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ABSTRACT 
 
I did my internship for my Master’s degree thesis at the Panum Institute, University 
of Copenhagen, Faculty of Health Sciences, Department of Cellular and Molecular 
Medicine, after winning an Erasmus Placement scholarship. 
Recent studies suggest the involvement of the BEX genes in cancer biology;  for 
example Bex1 (Brain Expressed, X-Linked) is overexpressed in neuroendocrine  
tumors and is downregulated in glioblastoma cells compared to normal tissue. 
Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as 
candidate tumor suppressor genes in malignant glioma. Moreover Bex1 is over-
expressed as a result of peripheral axonal damage and some studies also show 
an altered skeletal muscle regeneration in Bex1 knock out mice; therefore  Bex1 
could be considered as regeneration-associated gene. It is an adapter molecule 
involved in p75NTR/NGFR signaling and plays a role in cell cycle progression and 
neuronal differentiation. 
Many aspects of Bex1 are unknown so it is a an exciting field of research. Bex1 is 
expressed in central nervous system, lung, skeletal muscle, peripheral blood 
leukocytes, stomach, lymph node, trachea, bone marrow; highly expressed 
in pituitary, cerebellum, temporal lobe. Our attention was placed on the expression 
of Bex1 in normal and pathological liver tissues. Our study was focused on 
defining the mechanism by which Bex1 might regulate proliferation and 
differentiation of hepatic progenitor cells into the hepatic or cholangiocytic lineages 
during regeneration after tissue damage and in development of liver cancer. 
I used different methods in this project: Real Time-PCR, Immunohistochemistry, 
immunofluorescence and confocal microscopy, culturing of human hepatocellular 
carcinoma cell lines, Knock-Down in Huh7 cell line using  Dharmacon® Accell® 
siRNA with subsequent protein harvest, Bradford assay and Western Blot. 
The results of Real Time PCR show that there is an up regulation of Bex1 during 
liver regeneration after all liver diseases compared to donor liver. The 
immunolocalization in hepatic tissue shows a presence of Bex1 mostly in the bile 
duct and also in reactive ductular cells (RDCs) and hepatic progenitor cells (HPC). 
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The knock down of Bex1 in Huh7 cell line  shows a doubtful result, because we 
cobserved a reduction of our protein compared to control, but we expected Bex1 
at ~ 23kDa, while we found it at ~ 62kDa. There are maybe three explanations:  or 
the antibody recognizes an isoform of Bex in the cell line, or the protein have not 
been reduced sufficiently, or modifications of the protein are involved. 
For the future my aim is to examine the function of Bex1 as tumor suppressor in 
hepatocellular carcinoma and the role in signaling pathways regulating apoptosis. 
This whould likely allow a better understanding of the role that Bex1 plays in liver 
regeneration. 
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1 INTRODUCTION 
 
1.1 Brain Expressed X - Linked Gene Family 
Bex proteins are expressed from a family of “brain expressed X-linked genes” that 
are closely linked on the X-chromosome. 
The most commonly identified genes in these screens were members of the Bex 
(Brain expressed X-linked) gene family, rat Bex1 (Rex3), and a novel gene, rat 
Bex4. After identifying these genes, we then sought to characterize the Bex gene 
family. Two additional novel Bex genes (human Bex5 and mouse Bex6) were 
discovered through genomic databases. Bex5 is present in humans and monkeys, 
but not rodents, while Bex6 exists in mice, but not humans. Bex4 and Bex5 are 
localized to the X chromosome, are expressed in brain, and are similar in 
sequence. Bex4 and Bex5 are 54% and 56% identical to human Bex3 (pHGR74, 
NADE). Mouse Bex6 is on chromosome 16 and is 67% identical to mouse Bex4.  
In particular, Bex1 is also known as Rex3, Bex3 is also known as NADE / 
NGFRAP1 / HGR74, Bex4 is also known as BexL1, and Bex5 is also known as 
NGFRAP1L1. Ensembl divided the five human Bex genes into two gene families, 
with Bex1, Bex2, and Bex5 in one family, and Bex3 and Bex4 in the other. 
Fig.1 (Top) The exon–intron gene structure and the chromosomal arrangement of the Bex 
genes on chromosome X in human. (Bottom) The model of gene conversion explaining the 
pattern of sequence evolution in Bex. The brackets indicate the portions of Bex involved in 
gene conversion, and the arrows connect the Bex members involved in gene conversion. 
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Fig.2 Phylogenetic tree of the human (h), rat (r), and mouse (m) Bex genes. 
 
1.2 Discovery and Localization  
Functional assays have shown that BEX1 and BEX2 bind and interact with OMP 
(olfactory marker protein), and the interaction region likely covers amino acid 
positions 50–75, within which BEX1 and BEX2 show more than 92% identity. 
Conversely, the corresponding region in BEX3 shows less than 30% identity to 
BEX1 and BEX2, and therefore BEX3–OMP interaction is unlikely. BEX3 serves 
as a signaling adapter molecule and interacts with p75NTR to lead to programmed 
cell death in the presence of NGF (nerve growth factor). BEX1 recently has also 
been shown to interact with p75NTR and act as a molecular adapter linking 
neurotrophin signaling to the cell cycle. No functional roles have been assigned to 
the other members of the Bex family. The candidate sites for positive selection 
(sites 75, 81, 93, and 110) are mostly located in the tail region of the Bex genes, 
accounting for one-third of the entire gene. This region corresponds to the 
regulatory region in BEX3 (site 72–112) that is essential for NGF-dependent 
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regulation of BEX3-induced apoptosis, suggesting that positive selection has acted 
on Bex3 after gene duplication and there might have been evolution of a new gene 
function. As BEX1 can also bind to p75NTR but has not been found to play a role 
in apoptosis, it is clear that a more detailed functional comparison between BEX1 
and BEX3 is needed for a better determination of the specific functional 
divergence between the two genes. 
The BEX members show variation in their subcellular localization. BEX3 is found 
mainly in cytoplasm and has a nuclear export signal region (amino acid 90–100) 
that is essential for its export from the 
nucleus to the cytoplasm. BEX1 
however, is found predominantly in the 
nucleus, and BEX2 and BEX4 can be 
found in cytoplasm but through passive 
diffusion. A recent study showed that 
BEX1 can be found both in nucleus and 
cytoplasm, and its distribution from the 
nucleus to the cytoplasm can be 
regulated by NGF. BEX5, similar to BEX3, is found predominantly in cytoplasm, 
and its nuclear export signal region shows 50% identity to BEX3. Therefore, the 
phylogenetic relationship of these family members seems to reflect weakly the 
differentiation or similarity in subcellular localization of these members. 
The BEX members show great variation in their expression pattern. Human BEX1 
and BEX2 show similar expression patterns within the central nervous system but 
differ in other tissues, with BEX1 highly expressed in peripheral tissues and BEX2 
highly expressed in brain, pancreas, testis, and ovary, and expressed at a low 
level in other peripheral tissues. BEX3 is widely expressed, with the highest level 
of expression in liver. BEX4 has a remarkably high expression level in heart, 
skeletal muscle, liver and kidney. BEX5, similar to BEX3, is also widely expressed, 
with the highest levels in liver. Compared with the other Bex genes, Bex5 
generally tends to be present at lower levels. The duplication–degeneration–
complementation model suggests that degeneration of regulatory regions of 
duplicated genes may actually help to preserve functional copies after gene 
duplication; the great variation in the expression patterns of these Bex genes 
Fig.3 Eukaryotic Cell 
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appears to be consistent with this increasingly supported model, which explains 
why many duplicated genes in the genome remain functional after duplication. 
Human Bex gene expression was studied with tissue expression arrays probed 
with specific oligonucleotides. Human Bex1 and Bex2 have similar expression 
patterns in the central nervous system with high levels in pituitary, cerebellum, and 
temporal lobe, and Bex1 is widely expressed outside of the central nervous 
system with high expression in the liver. Human Bex4 is highly expressed in heart, 
skeletal muscle, and liver, while Bex3 and Bex5 are more widely expressed. Rat 
Bex3, rat Bex4, human Bex5, and mouse Bex6 are degraded by the proteasome, 
while rat Bex1 or Bex2 are not. Rat Bex3 protein can likely bind transition metals 
through a histidine-rich domain. The Bex gene family members are highly 
homologous but differ in their expression patterns, subcellular localization, and 
degradation by the proteasome. 
 
The gene structures are well conserved across family members and among the 
mammals in that all five members have three exons with the first two exons 
untranslated. Furthermore, the five members are arranged tandemly on 
chromosome X with Bex5, Bex1, Bex2 on the negative strand and Bex4, Bex3 on 
the positive strand, and this physical arrangement remains conserved among 
species. Sequence analyses indicate that gene conversion has been frequent and 
ongoing among Bex1-4, occurring in multiple species independently. All gene 
conversions in different species between Bex1 and Bex4, and between Bex2 and 
Bex3, appear to be limited to the upstream regions of the third exon, whereas the 
gene conversions occurred independently in different species between Bex1 and 
Bex2 and cover only the third exon. Bex5 appears to have little exchange of 
genetic information with other members, possibly due to its distance from other 
members. The GC content decreases from 5’-UTR, intron 1, intron 2, coding 
region, to 3’-UTR, reflecting faithfully the frequency of gene conversion in different 
regions of the Bex genes. Sequence analyses also suggest that both relaxed 
selective constraint and positive selection have acted on the Bex members after 
duplication. In particular, Bex3 shows strong evidence of positive selection and 
seems to have evolved a new gene function after gene duplication. 
To identify additional genes important in dopamine neuron differentiation, a 
laboratory performed subtractive hybridization screens on the developing ventral 
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mesencephalon (rat embryonic day 10) compared with dorsal mesencephalon and 
spinal cord. Of the 480 expressed sequence tag (EST) clones analyzed, the most 
commonly identified genes, comprising 12% of the ESTs, were members of the 
Bex (Brain-Expressed X-linked) gene family. The initial description of the Bex 
genes included three mouse genes sharing high sequence similarity, localization 
on the X chromosome, and high expression levels in the brain. One of the 
homologues that was identified was Bex1 (also named Rex3), which was first 
identified as a gene whose expression decreased after retinoic acid treatment of a 
mouse teratocarcinoma cell line.  
The examination of the chromosomal localization of the Bex genes and their 
expression in a wide range of human tissues showed that all of the Bex genes are 
translated, and that their protein products have differences in subcellular 
localization and degradation. 
There was the development and characterization of an antibody to mouse Bex1 
protein that cross-reacts with Bex2 (but not Bex3), and its use to determine the 
cellular distribution of Bex proteins  in the murine brain. The specificity of the 
antiserum was characterized by immunoprecipitation and Western blots of tissue 
and transfected cell extracts and by immunocytochemical analyses of cells 
transfected with either Bex1 or Bex2. Antibodies preabsorbed with Bex2 still 
recognize Bex1, while blocking with Bex1 eliminates all immunoreactivity to both 
Bex1 and Bex2. Bex immunoreactivity 
(ir) was primarily localized to neuronal 
cells within several regions of the 
brain, including the olfactory 
epithelium, bulb, peri/paraventricular 
nuclei, suprachiasmatic nucleus, 
arcuate nucleus, median eminence, 
lateral hypothalamic area, thalamus, 
hippocampus, and cerebellum. RT-
PCR and in situ hybridization demonstrated the presence of Bex mRNA in several 
of these regions.  
Double-label immunocytochemistry indicates that Bex-ir is colocalized with OMP in 
mature olfactory receptor neurons (ORNs) and in the OMP-positive subpopulation 
of neurons in hypothalamus.  
Fig.4 Olfactory marker protein 
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On the basis of the presently characterized distribution of Bex protein in the adult 
mouse brain, it is tempting to postulate that Bex proteins may participate in the 
control and integration of various aspects of feeding and regulation of body weight. 
This independent confirmation of Bex expression in rodent hypothalamus is 
consistent with the potential involvement of Bex in aspects of feeding or nutrition. 
Feeding behavior is very complicated and is regulated by several somatomotor 
and autonomic events in terms of searching for, selecting, eating, and digesting 
food. This process involves various forebrain circuits related to integration of 
olfactory and visual information, as well as many brainstem centers that regulate 
the behaviors of mastication and digestion in many of which we have observed 
Bex expression. 
 
1.3 Bex1 and p75NTR 
A screening for intracellular 
interactors of the p75 
neurotrophin receptor 
(p75NTR) identified brain-
expressed X-linked 1 
(Bex1), a small adaptor-like 
protein of unknown 
function. Bex1 levels 
oscillated during the cell 
cycle, and preventing the 
normal cycling and 
downregulation of Bex1 in PC12 cells sustained cell proliferation under conditions 
of growth arrest, and inhibited neuronal differentiation in response to nerve growth 
factor (NGF). In PC12 cells, Bex1 overexpression inhibited the induction of NF-kB 
activity by NGF without affecting activation of Erk1/2 and AKT, while Bex1 
knockdown accelerated neuronal differentiation and potentiated NF-kB activity in 
response to NGF. Bex1 competed with RIP2 for binding to the p75NTR 
intracellular domain, and elevating RIP2 levels restored the ability of cells 
overexpressing Bex1 to differenziate in response to NGF. Together, these data 
establish Bex1 as a novel link between neurotrophin signaling, the cell cycle, and 
 Fig.5  Binding of nerve growth factor 
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neuronal differentiation, and suggest that Bex1 may function by coordinating 
internal cellular states with the ability of cells to respond to external signals. 
Nerve growth factor (NGF) and other members of the neurotrophin family mediate 
survival, growth and differentiation of neuronal and glial cells by binding to two 
different types of cell surface receptors, the Trk tyrosine kinases—TrkA, TrkB and 
TrkC—and the p75 neurotrophin receptor (p75NTR). p75NTR resembles other 
members of the tumor necrosis factor receptor superfamily in the organization of 
its extracellular domain and in the presence of a small globular domain in the 
intracellular region, the so-called death domain. p75NTR signaling can contribute 
to neurotrophin- mediated survival, differentiation and neurite outgrowth in a 
variety of neuronal subpopulations. On the other hand, p75NTR can also mediate 
cell death by neurotrophins, proneurotrophins and various amyloid peptides, as 
well as inhibit axonal growth and regeneration in its capacity of signaling receptor 
for myelininhibitory components. 
Trk receptors transmit intracellular signals through several of the canonical 
pathways activated by other receptor tyrosine kinases, including the Ras/MAP 
kinase and phosphatidylinositol- 3 kinase. In contrast, the signaling mechanisms 
used by p75NTR have remained elusive. Lacking intrinsic catalytic activity, 
p75NTR signaling is dependent on the ability of this receptor to interact with 
components of intracellular signaling pathways. Several different p75NTR 
interacting molecules, with and without catalytic activity, have been identified to 
date. Noncatalytic interactors include a series of scaffoldingand adaptor-like 
molecules, such as caveolin-1, Bex3/NADE  and TRAF6; larger proteins 
containing zinc-finger domains with some degree of nuclear localization, such as 
NRIF1/2  and SC-1; and members of the MAGE homology domain family, such as 
NRAGE and necdin, with proposed roles in the regulation of apoptosis. p75NTR 
interactors with catalytic activity include serine–threonine kinases involved in 
interleukin and NF-kB signaling, such as IRAK and RIP2; a protein tyrosine 
phosphatase (FAP-1); and the small GTPase RhoA. How these p75NTR-
interacting proteins connect to downstream signaling pathways and cellular 
responses is less clear, however. 
A C-terminal fragment of the rat ortholog of a human protein originally named 
Bex1  was isolated in a T7 phage display screen for interacting partners of the 
intracellular domain of p75NTR. Bex1 and Bex2 are very similar in protein 
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sequence (87% identity), while Bex3/ NADE—a previously characterized interactor 
of the p75NTR death domain—is only 30% identical to either Bex1 or Bex2 and 
thus represents a more divergent member of this family. Despite their low 
similarity, the main region in Bex3/NADE implicated in its interaction with p75NTR 
was included in the Bex1 cDNA fragment isolated by phage display, suggesting 
the existence of a conserved p75NTR-binding interface among Bex proteins. 
Expression of Bex1, Bex2 and Bex3 mRNAs could be detected by RT–PCR in 
PC12 cells and primary cultures of embryonic day (E) 14.5 rat dorsal root ganglion 
(DRG) cells. Only Bex1 and Bex3 mRNAs could be found in Schwann cells 
isolated from the newborn rat sciatic nerve and in E17.5 hippocampal cultures. 
mRNAs encoding all three Bex isoforms could also be detected in newborn (P1) 
cerebral cortex, hippocampus and olfactory bulb. Bex1 mRNA expression could be 
localized more precisely by in situ hybridization within specific regions of the 
developing rat embryo. At E13.5, Bex1 mRNA was widely expressed throughout 
the developing nervous system and in vascular and mesenchymal structures. In 
particular, prominent Bex1 mRNA expression could be observed in the somitic 
mesenchyme, heart, aorta, dorsal root ganglia, sympathetic ganglia and the lateral 
motor columns of the developing spinal cord, all tissues known to express high 
levels of p75NTR mRNA at this stage. At later stages of brain development, Bex1 
mRNA was also observed in structures known to express p75NTR mRNA, 
including the olfactory bulb, striatum, 
thalamus, cerebral cortex and 
hippocampus. 
Bex1 expression recovered in arrested 
cells after prolonged NGF treatment and 
concomitantly with postmitotic neuronal 
differentiation, in agreement with the 
abundant Bex1 expression observed in 
postmitotic neurons in vivo. In order to 
examine the regulation of Bex1 levels 
during the cycle, cell cultures were synchronized in G1 by 24 h serum starvation, 
after which serum was added back to initiate cell cycle re-entry. Bex1 levels were 
largely restored 12 h after serum re-addition, as the cells entered S phase, and 
then decreased again 36–48 h thereafter, as cells returned to G1. A second peak 
Fig.6  Cell Cycle 
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in Bex1 was observed as cells re-entered S phase 72 h after serum addition. 
Thus, the levels of endogenous Bex1 oscillated during the cell cycle in a pattern 
that resembled that of p75NTR expression in the membrane of PC12 cells, which 
had previously been found to be maximal during S phase and lowest during early 
G1. Serum starvation of PC12 cells did not affect the steady state level of Bex1 
mRNA, indicating a posttranscriptional regulation of Bex1 levels. Using the protein 
synthesis inhibitor cycloheximide, the half-life of Bex1 was estimated at 
approximately 5 h in exponentially growing cells. Upon serum withdrawal, 
however, Bex1 declined even more rapidly, falling below detection levels between 
30 and 90 min after serum deprivation. Interestingly, this decline could be 
prevented by treatment with the proteasome inhibitor PS I, confirming that Bex1 
levels are regulated by protein degradation. 
A motif in the C-terminal portion of the protein (100RERQLS105) matched the 
consensus site for phosphorylation by the serine threonine kinase AKT 
(RxRxxS/T). After metabolic labeling of 293 cells with 32P-orthophosphate, 
incorporation of 32P was observed in wild-type Bex1, but not in a mutant with a 
Ser105 to Ala substitution, indicating that Ser105 is an endogenous 
phosphorylation site in this protein. In addition, no phosphorylated Bex1 could be 
detected after treatment with LY294002, an inhibitor of PI3K, the upstream 
activator of AKT. Moreover, reduction of endogenous AKT activity by serum 
withdrawal also attenuated Bex1 phosphorylation. In in vitro kinase assays, wild 
type, but not mutant, Bex1 was readily phosphorylated by wild-type AKT, while 
kinase-dead AKT had no effect, indicating that Bex1 is a direct target of AKT in 
vitro. Using antibodies that recognize a phosphorylated consensus substrate site 
for AKT, an increase in the phosphorylation of a band corresponding to Bex1 could 
be observed in PC12 cells treated with NGF, a stimulus that is known to acutely 
activate AKT in these cells. Bex1S105A was consistently expressed at levels 
lower than wild-type Bex1 in exponentially growing cells, suggesting a role for 
Ser105 phosphorylation in regulating the stability of the protein. In agreement with 
this, treatment with the proteasomal inhibitor PS I produced a significant increase 
in the levels of Bex1S105A. Using PS I, we could also confirm that the reduced 
phosphorylation of the S105A mutant observed in 293 cells was not due to its 
otherwise low level of expression. Taken together, these results indicated that 
Bex1 can be phosphorylated in Ser105 by AKT, and that this event regulates Bex1 
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protein turnover. There is not any significant increase in cell death after transient 
transfection of GFP-Bex1 in PC12 cells, nor in stable PC12 clones overexpressing 
Bex1. Parental PC12 cells and clones overexpressing Bex1 showed no 
differences in cell cycle progression during exponential growth. However, upon 24 
h serum withdrawal, a larger proportion of cells in clones C4 and E2 were in S 
phase compared to parental cells, suggesting that Bex1 overexpression may have 
interfered with cell cycle arrest. Incorporation of BrdU was examined under two 
growth-arrest conditions, that is, serum withdrawal and NGF treatment. Strikingly, 
cells overexpressing Bex1 continued proliferating at normal levels under either 
condition, indicating a failure to exit the cell cycle as a result of deregulated Bex1 
expression. Following 5-day treatment with NGF in low serum, clones 
overexpressing Bex1—as well as transiently transfected cells—failed to 
differentiate, and showed only incipient signs of neuronal differentiation. Taken 
together, these results indicated a role for Bex1 in cell cycle progression and 
neuronal differentiation. 
 
1.4 Bex1 during Skeletal Muscle Regeneration 
 
Bex1 and Calmodulin (CaM) are up regulated during skeletal muscle regeneration. 
The study about the role of Bex1 and its interaction with CaM in skeletal muscle 
regeneration, used Bex1 knock out (Bex1-KO) mice. These mice appeared to 
develop normally and are fertile, but displayed a functional deficit in exercise 
performance compared to wild type (WT) mice. After intramuscular injection of 
cardiotoxin, which causes extensive and reproducible myotrauma followed by 
recovery, regenerating muscles of Bex1-KO mice exhibited elevated and 
prolonged cell proliferation, as well as delayed cell differentiation, compared to WT 
 Fig.7  Skeletal Muscle 
Regeneration 
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mice. The results provide the first evidence that Bex1-KO mice show altered 
muscle regeneration, so the interaction of Bex1  with Ca2+/CaM may be involved in 
skeletal muscle regeneration. 
Skeletal muscle is a very adaptable tissue and can regenerate after injury. The 
process of skeletal muscle repair is a dramatic response to damage. Regeneration 
is the result of many biological processes, such as inflammation, angiogenesis, 
arteriogenesis, and myogenic progenitor cell mediated myogenesis, all of which 
lead to the reconstitution of functional skeletal muscle tissue. When this controller 
repair system is impaired, continuous muscle degeneration and regeneration can 
occur. Such is the case with Duchenne’s muscular dystrophy (DMD), the most 
common form of inherited neuromuscular disorder. Experiments performed using 
cDNA-based microarrays have identified highly coordinated molecular changes 
involved in skeletal muscle regeneration following cardiotoxin (CTX)-induced 
injury, a reproducible method to induce muscle regeneration. Mdx mice possess a 
mutation in the gene coding dystrophin, the protein that is absent in humans with 
DMD. Histological findings, such as centrally nucleated fibers, inflammation, and 
heterogeneity of fiber size, are similar in the skeletal muscle of mdx mice and of 
patients with DMD. In comparison to controls, many genes are differentially 
expressed in mdx mouse muscle. Interestingly, the differential expression of Bex1 
(Rex3) and Calmodulin (CaM). Expression of Bex1 is transiently elevated at the 
end of the proliferation state of skeletal muscle regeneration and several studies 
implicate the Bex1 protein in cell growth and differentiation. To confirm the 
interaction of Bex1 with CaM, the ability of recombinant Bex1 protein to bind CaM 
was analyzed by an electrophoretic mobility shift assay in the presence of Ca2+. 
The interaction of Bex1 and CaM was determined  to be Ca2+-dependent. Bex1 
expression is elevated following activation of skeletal muscle degeneration and 
regeneration in response to CTX-induced muscle injury. Bex1 expression was only 
induced in CTX-treated WT mice, further confirming the specificity of the Bex1-KO. 
Although mice lacking Bex1 are viable and fertile, their exercise performance 
measurements were 24% lower than WT mice. This finding is consistent with the 
report that Bex1 protein is highly expressed in developing muscle, where it is 
localized in somatic mesenchyme. 
 The lack of Bex1 in mice may alter normal 
development of muscle and lead to a reduction in 
exercise performance.
expression in regenerating
markers of myogenesis to characterize
and WT mice after CTX injection.
The virtual absence of Bex1 mRNA in
the presence of a small amount of Bex1
days after CTX injection, followed by a dramatic 
elevation after 5 days. Approximately 5 days after
injury, when Bex1 is dramatically induced, myogenic 
cells withdraw from the cell cycle and either self
renew or form differentiated myotubes that contain central nucle
this differentiation, cell cycle dependent
p27KIP1 and p57KIP2, together with myogenin, are induced to prevent
reentering the cell division cycle
Increased expression of CDKIs and myo
myogenic differentiation.
script levels of each gene at 5 days after CTX
p57, and myogenin were reduced
by more than 27%, 40%, and 50%, respectively.
were similar between both
and p57 were reduced in the 
is essential to monitor the level
important since these proteins were reported to be regulated by
degradation. 
There are no expression of p21, p27
However, there was increased expression of these CDKIs at the initial stage
myogenic differentiation at 5
The levels of p27 and p57 proteins
KO compared to that of WT mice at 7
The investigations show that Bex1 protein binds CaM in a calcium
manner, Bex1- KO mice exhibit reduced treadmill exercise performance compared 
to WT mice, and the absence of Bex1 protein in mice results in increased and 
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 muscle, the study used 
 Bex1-KO 
 
 controls and 
 transcript 3 
 
-
-kinase inhibitors (CDKI) such as p21CIP1, 
. 
genin are hallmarks
 Semi-quantitative RT-PCR was used to determine 
-injury. The transcript levels of p27, 
 in regenerating muscle of Bex1
 By contrast, 
 groups. Even though the mRNA transcript levels of p27
regenerating muscle of Bex1- KO mice by 
 of expressed functional protein. This is particularly 
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prolonged proliferation and delayed differentiation in skeletal muscle post CTX-
induced injury. This suggests that Bex1-KO mice should show better muscle 
function compared to the WT mice.  
 
1.5 Bex1 during Axonal Regeneration 
Numerous external inhibitory factors 
inhibit axonal regeneration after injury. In 
response, neurons express various 
regeneration-associated genes to 
overcome this inhibition and increase the 
intrinsic growth capacity. One recent 
study showed that the brain expressed 
X-linked (Bex1) protein was over-
expressed as a result of peripheral 
axonal damage. Bex1 antagonized the 
axon outgrowth inhibitory effect of 
myelin-associated glycoprotein. The 
involvement of Bex1 in axon regeneration was further confirmed in vivo. The study 
demonstrated that Bex1 knock-out mice showed lower capability for regeneration 
after peripheral nerve injury than wild-type animals. Wild-type mice could recover 
from sciatic nerve injury much faster than Bex1 knock-out mice.  
The study first analyzed the expression of Bex1 in cultured MNs prepared from 
E13-14 mice. MNs (motor neurons) were fixed at 3 days in vitro and analyzed by 
immunofluorescence to determine the subcellular localization of Bex1. Anti-Tau-1 
andanti-MAP2 antibodies were used as markers for axons and minor neurites, 
respectively Bex1 was present in the soma and was detectable in all neurites in a 
punctate staining pattern. No selective enrichment in axons or minor neurites was 
apparent. 
 
Fig.9  Motor Neuron (MN) 
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Fig.10 Bex1 expression in axons. MNs from E13-14 mouse embryos were fixed at 3 days in 
vitro (DIV) and stained with antibodies specific for Bex1 (green), MAP2 (red) and the Tau-1 
antibody (blue). The scale bar is 40 μm. 
 
The finding that Bex1 expression is up-regulated in the MNs after different types of 
axonal injury suggests that Bex1 might be involved in the regeneration of 
damaged axons. 
 
 
 
 
Fig.11 The expression of Bex1 protein, the tissue sections from lumbar-spinal cord of MPZ-
KO and MAG-KO mice and mice subjected to sciatic-nerve crush-injury or demyelination 
were stained with anti Bex1 (green) and anti-non-phosphorylated neurofilament (SMI32; a 
marker of neurons) (red) antibodies. 4’,6-Diamidino-2-phenylindole dihydrochloride 
hydrate (blue) was used for nuclear staining. Scale bar is 50 μm. 
 
These Bex1-KO mice were viable and fertile and indistinguishable from WT 
littermates and developed normally. The axons and myelin of Bex1-KO peripheral 
nerves appeared normal. Motor coordination and balance were tested on the 
rotarod at 8 weeks of age and no deficits were recorded in the knock-out mice. 
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Most of the motor axons were injured as demonstrated by a significant reduction of 
61% in the number of retrogradely labeled MNs in the spinal cords of sciatic nerve-
injured mice compared with sham-operated mice 7 days after the nerve crush. 
These results indicate that the WT mice exhibited more rapid axonal regeneration 
than the KO mice. 
The recovery of motor/sensory function was compared between WT (n = 5) and 
Bex1-KO (n = 5) mice on 7, 14, 21 and 28 days post-injury, using the Rotarod test 
to measure the motor coordination and balance, gait analysis with SFI and the toe- 
pinch reflex analysis. Acute functional deficits compared with baseline 
performance were observed for both WT and Bex1-KO groups at day 7 [WT = 
3.6%, KO = 4%; percentage (%) of mean duration compared with the presurgery 
control value] and day 14 (WT = 17%, KO = 16%) after injury although there was 
no significant difference in Rotarod results between Bex1-KO mice and WT 
littermates at these time-points.  
WT performance recovered more rapidly and up to 49 % of baseline at day 21 and 
72% of baseline at day 28 whereas Bex1-KO mice showed significantly lower 
recovery (29% of baseline at day 21 and 59% of baseline at day 21; p < 0.01, 
ANOVA). Although both groups had similar baseline-performance ability before 
injury and exhibited similar deficits on days 7 and 14 after injury, their performance 
abilities differed significantly between WT and KO animals on day 21 (p < 0.01, 
ANOVA) and day 28 (p < 0.01, ANOVA). The muscle injury recovered within 2 
weeks and it seems that the major contribution to the observed difference between 
WT and Bex1-KO mice after sciatic-nerve injury was related to delayed axonal 
regeneration rather than muscle regeneration. At 14 days post-injury, the recovery 
of Bex1-KO mice was significantly less complete than in the WT littermates (p < 
0.01, ANOVA). Both WT and Bex1- KO mice recovered to the same level after 28 
days. 
The study demonstrated that mice deficient in Bex1 protein possess a reduced 
capability to regenerate injured axons than do WT littermates. There are 
evidences that this effect maybe partially arised from the function of Bex1 on 
modulation of RhoA activation after injury, which would ultimately result in better 
axonal growth. However, Bex1 could be also involved in re generation via another 
mechanism. Bex1 can interact with calmodulin, and it may be involved in the 
signaling pathway by which receptor-mediated calciumfluxes regulate growth-cone 
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activity. Bex1 should be considered to be a RAG because may play a role in 
promoting nerve repair after injury in the PNS. These findings open interesting 
possibilities for exploring Bex1 function in the control of neuronal regeneration in 
the CNS. 
 
1.6 Bex1 as Tumor Suppressor 
Epigenetic silencing of tumor suppressor genes is a common motif in human 
cancer. Tumor-associated transcriptional silencing is most frequently described in 
association with a few common underlying epigenetic mechanisms, such as 
promoter, histone deacetylation, histone methylation, and other histone 
modifications, which directly or indirectly alter chromatin structure. 
Several recent studies have validated this large-scale approach using DNA 
methyltransferase and histone deacetylase (HDAC) inhibitors, either alone or in 
combination, in a variety of human cancers, including pancreatic, colon, prostate, 
liver, endometrial, blood, and esophageal cancers.  
The scope of epigenetic gene 
silencing in malignant glioma has 
not been well defined. Malignant 
glioma, the most aggressive and 
common brain tumor in adults. 
Promoter hypermethylation and 
epigenetic silencing of the DNA 
repair gene O6-methylguanine-DNA 
methyltransferase were shown to 
identify a subset of patients with 
markedly improved survival at 2 years in response to combined treatment with 
chemotherapy and radiation  therapy. Several other genes critical for cell 
proliferation, tumor progression, apoptosis, angiogenesis, and astrocyte motility 
have also been shown to be silenced in association with promoter 
hypermethylation in malignant glioma. 
Abundant evidence supports a synergistic link between promoter hypermethylation 
and histone deacetylation in the active suppression of gene transcription. 
Importantly, several recent reports suggest that pharmacologic inhibition of histone 
deacetylation alone markedly reverses transcriptional silencing, even in the 
Fig.12  HDAC inhibition 
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absence of promoter hypermethylation. This has led to the hypothesis that histone 
deacetylation is the primary mechanism that actively modulates epigenetic 
transcriptional silencing. HDAC inhibitors have subsequently emerged as a 
powerful new class of chemotherapeutic agents with promising antitumor effects. 
In immortalized glioma cell lines, HDAC inhibition results in cell cycle arrest and 
increased apoptosis.  
BEX1 and BEX2, both strongly induced by TSA and 5-AzaCin glioma cell lines that 
were found to be silenced in all glioma tumor specimens when compared with 
nontumor brain specimens. The Real-Time PCR confirmed the activation of BEX1 
and BEX2 in response to TSA and 5-AzaC treatment. Analysis of CpG islands in 
the promoter region of BEX1 and BEX2 shows that both genes have differentially 
methylated CpG sites in tumor samples compared with normal brain samples. The 
increased methylation of the promoter-associated CpG islands correlated with the 
decreased expression of BEX1 (P < 0.05) and BEX2 (P < 0.05) in the tumor 
tissues. The study characterized BEX1 and BEX2 promoter methylation in the T98 
and U87 cell lines before and after treatment with TSA and 5-AzaC. BEX1 is 
densely methylated in both T98 and U87 cells, whereas BEX2 is only methylated 
in T98 cells. 
Using adenoviral transfection constructs, the researchers expressed BEX1 and 
BEX2 individually in malignant glioma cell lines to determine potential tumor 
suppressor function. Expression of BEX1 and BEX2 was independently confirmed 
by real-time PCR. Expression of either BEX1 or BEX2 resulted in a marked 
decrease in colony formation compared with control transfected cells in both T98 
and U87 immortalized cell lines. 
There was no increase in apoptotic cells after BEX1 or BEX2 transduction alone 
as measured by TUNEL staining. After treatment with a subtherapeutic dose of 
camptothecin and etoposide, two chemotherapeutic agents known to induce 
apoptosis in glioma cells at higher doses, there was a striking increase in the 
number of cells undergoing apoptosis in the BEX1 and BEX2 transduced 
population when compared with control vector-treated cells. Finally, the 
researchers BEX1- or BEX2-transduced U87 cells in a nude mouse model to 
measure in vivo tumor growth. There is marked suppression of tumor growth in 
BEX1- or BEX2-transduced cells when compared with control vectortransduced 
cells (P < 0.01). These results support a tumor suppressor role for both BEX1 and 
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BEX2 in malignant glioma. Reexpression of either BEX1 or BEX2 suppresses 
tumor growth and chemosensitizes malignant glioma cells to camptothecin-
induced apoptosis. 
Epigenetic silencing of tumor suppressor genes in human cancer is widespread, 
involving signaling pathways controlling angiogenesis, cellular proliferation, 
migration, apoptosis, and differentiation. Densely methylated DNA is associated 
with deacetylated histones and compacted chromatin, which is refractory to 
transcription. Several members of a family of methylbinding domain proteins have 
been shown to associate with large protein complexes containing HDAC, histone 
methylase, and chromatin-remodeling enzymes. Promoter methylation as a 
biomarker for disease detection and prognosis has been validated in prostate, 
lung, and bladder cancer. Recent reports indicate that many of these methylation 
markers can be detected in serum and other body fluids with methylation-specific 
PCR techniques. The correlation of specific epigenetic signatures with disease 
state, progression, and response to treatment holds great promise for the 
development of therapeutic advances targeted to genetically stratified patients.  
The study identified and further characterized the tumor suppressor function of two 
of these genes, BEX1 and BEX2, in malignant glioma. BEX1 and BEX2 are X-
linked uncharacterized cDNAs that have 91% sequence similarity with each other. 
Proteins coded by both these genes contain the BEX domain. Interestingly, this 
domain is also present in human p75NTRassociated cell death executor (NADE) 
protein, which has been implicated in the p75-mediated signal transduction 
pathway. NADE has been shown to have diverse effects on the central nervous 
system, including differentiation and apoptosis. BEX1 and BEX2 may play an 
important role in a novel signaling pathway regulating apoptosis in malignant 
glioma.  
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1.7 Architecture of the Liver and Regeneration 
 
1.7.1 Architecture 
 
To understand the molecular 
basis of hepatogenesis it is first 
necessary to first consider the 
structure of the adult liver. In 
contrast to most complex organs, 
histological sections through the 
liver reveal a rather homogeneous 
landscape of hepatocytes 
periodically infiltrated with 
vascular tissue and bile ducts.  
This somewhat bland histological 
appearance masks an extremely complex and under appreciated tissue 
architecture that is crucial for normal hepatic function . The basic architectural unit 
of the liver is the liver lobule. The lobule consists of plates of hepatocytes lined by 
sinusoidal capillaries that radiate toward a central efferent vein. Liver lobules are 
roughly hexagonal with each of six corners demarcated by the presence of a portal 
triad of vessels consisting of a portal vein, bile duct, and hepatic artery. Both the 
portal vein and hepatic artery supply blood to the lobule, which flows through a 
network of sinusoidal capillaries before leaving the lobule through the central vein. 
Although hepatocytes are the major parenchymal cell type of the liver and account 
for 78% of liver volume, they function in concert with cholangiocytes (biliary 
epithelial cells), endothelial cells, sinusoidal endothelial cells, Kupffer cells 
(resident liver macrophages), pit cells (natural killer cells), and hepatic stellate 
cells. The hepatocytes, which are polarized epithelial cells, are arranged as cords 
that are one cell thick in mammals. The basolateral surfaces of the hepatocyte 
face fenestrated sinusoidal endothelial cells, which facilitates the transfer of 
endocrine secretions from the hepatocytes into the blood stream. Tight junctions 
formed between neighboring hepatocytes generate a canaliculus that surrounds 
each hepatocyte and is responsible for collection of bile acids and bile salts that 
are transported across the hepatocyte’s apical surface. Bile collected by the 
Fig.13  Overall structure of a portion of a liver 
lobule 
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canaliculi is carried to the bile ducts within the portal triad and subsequently 
transported for storage in the gall bladder. The complex arrangement between the 
polarized hepatocytes with the capillaries and cholangiocytes underlies both 
endocrine and exocrine functions of the liver. The challenge facing developmental 
biologists is to understand the molecular events that lead to the generation of each 
cell type within the liver and to determine how the cells arrange to form the three-
dimensional architecture that is so crucial for hepatic function. 
 
1.7.2 Regeneration 
 
 
 
The unique ability of the liver to regenerate itself has fascinated biologists for 
years and has made it the prototype for mammalian organ regeneration. It is now 
well accepted that there are two physiological forms of regeneration in the liver as 
responses to different types of liver injury. At the frontline of defense are mature, 
normally quiescent adult hepatocytes, and in the majority of liver injuries due to 
drugs, toxins, resection, or acute viral diseases, hepatocytes are the main cell type 
to proliferate and regenerate the liver. The second layer of defense lies in the 
reserve progenitor cell population, which is also a quiescent compartment in the 
liver, but is activated when injury is severe, or when the mature hepatocytes can 
no longer regenerate the liver due to senescence or arrest. A particularly 
fascinating point about this process is that the degree of hyperplasia is precisely 
Fig.14  The two levels of liver regeneration 
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controlled by the metabolic needs of the organism, such that the process stops 
once an appropriate liver to body weight ratio is achieved. PH is reproducible and 
leads to a proliferative stimulus that is initiated by an inflammatory stimulus, in the 
absence of significant cell death. 
Regeneration of the liver is critical to the survival of mammals and is therefore 
evolutionarily conserved.  Virtually all cellular machinery be activated during 
regeneration, and that this could realistically entail hundreds of pathways. It is 
proposed that there is an initial activation of the cytokine cascade in Kupffer cells, 
which then stimulates growth factor and metabolic pathways in hepatocytes. Other 
non parenchymal cells (stellate cells, vascular and biliary endothelial cells) 
proliferate after hepatocytes, presumably responding to yet another set of signals. 
A great deal of recent work has focused on how pattern recognition receptors and 
a variety of inflammatory molecules are activated and initiate the cytokine 
signaling cascade after PH. In brief, involved pathways include (at least) the 
activation of nuclear factor-kappa B (NF-kB) in Kupffer cells via tumor necrosis 
factor (TNF), lymphotoxin (from T cells), MyD88  and/or complement components,  
with downstream secretion of interleukin-6 (IL6). In turn, IL-6 binds its receptor on 
hepatocytes and leads to activation of the transcription factor signal transducer 
and activator of transcription 3 (STAT3).15 Fascinating newer work in mice with a 
hepatocyte-specific deletion of inhibitor-of-kappaB-kinase 2 (IKK2), which normally 
acts to activate NF-kB, demonstrated earlier and increased NF-kB activation in 
Kupffer cells, which had intact IKK2, with a concomitant decrease in NF-kB 
activation in hepatocytes. These animals had more rapid hepatocyte proliferation 
than control littermates, perhaps via prolonged JNK activation, highlighting both 
the cross talk between different cell types during liver regeneration and the critical 
importance of inflammatory stimuli in priming hepatocytes for replication. After 
cytokines have triggered the G0 to G1 transition, several secondary signals then 
stimulate progression through the cell cycle. These growth factors are numerous 
and redundant to a great extent, again highlighting the physiologic importance of 
liver regeneration to the survival of the animal. Hepatocyte growth factor (HGF) is 
another key hepatic mitogen active following PH. It is released from the 
extracellular matrix following PH to bind its receptor, c-Met, on the surface of 
hepatocytes. Conditional deletion of c-Met in the livers of mice was initially shown 
to cause either a significant delay in cell cycle entry after PH,or an inability to 
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survive the procedure. Studies using RNAi against HGF or c-Met in rats supported 
the former study, showing a suppression of cell proliferation with successful 
knockdown of this pathway. A family of proteins that appears to function across 
signaling networks is the matrix metalloproteinase (MMP) family. Through studies 
of animals genetically modified to lack inhibitors of MMPs (tissue inhibitors of 
MMPs, or TIMPs), MMPs have been shown to be important in the cleavage and 
release of growth factors from the extracellular matrix. Specifically, TIMP1 loss of 
function leads to increased MMP activity after PH, with increases in HGF activity 
and accelerated cell proliferation. Accordingly, a gain of TIMP1 function lead to a 
delay in cell proliferation. The metabolic challenges facing the regenerating liver 
are quite impressive. The liver must continue to regulate systemic Energy levels 
while meeting its own demands for significant nucleotide and protein synthesis 
needed for cell division. In fact, some of the most profound phenotypes seen in 
genetically-modified mice after PH have been demonstrated in those with defects 
in the phosphoinositide-3 kinase (PI3K) pathway. Important downstream effectors 
of this pathway include Akt, which activates mTOR and appears to affect cell size 
specifically and p70 S6 kinase, which regulates the 40S ribosomal protein S6 to 
control protein synthesis and cell proliferation. The Wnt/beta-catenin pathway has 
been extensively studied in a myriad of developmental processes in a variety of 
organs; liver regeneration is no exception. Using reporter mice, some investigators 
have demonstrated activation of this pathway after PH, while others have 
suggested that the canonical Wnt pathway is preferentially activated during the 
proliferation of oval cells (a type of progenitor cell).  
Gene expression profiling was recently used to examine the differential 
proliferative response that occurs after 1/3 (minimal proliferation) versus 2/3 PH 
(robust proliferation). It was found that even 1/3 PH leads to significant changes in 
gene expression. Interestingly though, between 4 and 12 h after the two 
operations, a transcriptional shift seemed to occur, committing hepatocytes toward 
replication. This transcriptional shift consisted of the activation of genes enriched 
in transcription regulatory elements for FOXD3, FOXI1, CUX1, ER and E2F-1 at 4 
h after 2/3 PH, and their replacement at 12 h by genes enriched in TREs for c-jun, 
CCAAT box, Myb, Ets-1, Elk-1 and USF, which are associated with DNA 
replication. These data demonstrate that the liver initially responds to PH with 
massive changes in gene expression, even if the operation does not result in DNA 
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replication, and suggest that genomic and epigenomic changes function as a 
“wake up” call for quiescent hepatocytes to prepare them for the decision to 
replicate, which occurs 12 h after PH or later. 
Additionally, further work in genetically modified mouse models has lead to the 
discovery of novel and at times unexpected factors that drive hepatocyte 
proliferation after resection. One such development was the description of the 
critical role of platelets and platelet-derived serotonin in liver regeneration. In 
particular, these investigations demonstrated that thrombocytopenic mice (or mice 
with a variety of functional platelet defects) had a significant impairment in 
hepatocyte proliferation after PH. Other recent work has focused on the role of the 
extracellular matrix in determining the appropriate size of the liver at the 
completion of regeneration, i.e. regulating the termination phase of regeneration. 
Mice with a hepatocyte-specific loss of integrin-linked kinase subjected to PH, 
were left with livers an average of 58% larger than their original weights. 
 
When hepatocytes are prevented from proliferating, liver progenitor cells serve as 
the second line of defense against liver failure.  Farber first descrive the presence 
of a liver progenitor cell population in 1956 when he noted the presence of small 
cells with high nuclear-cytoplasmic ratio and called them “oval cells”. These cells 
were activated in animal models of liver injury and had bipotential ability to 
differentiate into hepatocytes 
and bile duct cells. 
The adult human equivalent 
of these progenitor cells have 
been localized to the terminal 
bile ductules, known as the 
canals of Hering. This 
quiescent cell population acts 
as reserve population to be 
activated only when the adult 
hepatocytes are not able to 
repair and regenerate the 
injured liver, either due to 
senescence or cell cycle Fig.15  Oval cell proliferation 
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arrest due to liver toxins such as alcohol. Upon activation, these progenitor cells 
proliferate in the portal zone and are seen as a collection of progenitor cells and 
cells of intermediate differentiation.  The “streaming liver hypothesis”  proposes 
that these cells then migrate toward the central vein in the liver lobules as 
progressively differentiated daughter hepatocytes. Using mitochondrial DNA 
mutation tracking, this was demonstrable in the normal human liver as well as in 
regenerative nodules of liver cirrhosis.  
The observation that liver progenitor cells have mixed epithelial and mesenchymal 
markers and the ease by which mesenchymal stem cells can be converted to 
hepatocyte-like cells raised the possibility that they may arise from the 
mesenchymal lineage via mesenchymal to epithelial transition. In light of 
conflicting evidence, the role of epithelial-mesenchymal transition and vice versa in 
liver injury and repair remains highly controversial.  The role of progenitor cell 
regeneration in normal liver physiology is still debated. These cells likely have no 
significant role in dayto- day liver turnover. The progenitor compartment is 
activated only in severe liver injury, and the belief that it plays an important role in 
regenerating the injured liver comes from three lines of evidence. First, progenitor 
cells are present in advanced stages of many human liver diseases in which native 
hepatocytes are believed to be senescent or inhibited from proliferating, such as 
alcoholic and non-alcoholic cirrhosis, chronic viral hepatitis, and primary biliary 
cirrhosis. The presence of these cells directly correlates with both inflammation 
and the degree of liver injury; patients with higher MELD scores appear to have 
more progenitor cell activation. Second, studies of chronic viral hepatitis in human 
patients showed that these progenitor cells are indeed surrounded by hepatocyte-
like cells of intermediate differentiation, suggesting ongoing regeneration. 
Interestingly, although ductular proliferation is also seen after bile duct ligation and 
in primary biliary cirrhosis, the response in these systems is believed to come from 
cholangiocytes rather than progenitor cells.  
A stem cell environment, or “niche”, is believed to maintain the liver progenitor cell 
in its native state, and allows for regulatory signals to activate it when required. 
The companion supportive cells in this niche have long been suspected to be 
mesenchymal cells, such as portal fibroblasts, hepatic stellate cells or vascular 
endothelial cells. 
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2 MATERIALS AND METHODS 
 
2.1 RNA Isolation 
 
Obtaining high quality, intact RNA is the first and often the most critical step in 
performing many fundamental molecular biology experiments, the RNA isolation 
procedure should include some important steps both before and after the RNA 
purification.  
 
For cell culture: 
The growth media was removed from wells and the cells were washed in PBS and 
lysed directly by adding 170µl TRIzol® Reagent** to each well.  
 
For whole liver tissue: 
 
20-30mg liver tissue were added (fresh or snap frozen in liquid nitrogen and stored 
at -80°C) to 1ml TRIzol® Reagent in 2ml RNase free Eppendorf tube and 
homogenized by means of a TissueLyser (Qiagen, Retsch, Germany). 
 
[Lysate solution can be stored at -60 to -70°C for at least one month]. 
 
200µl of chloroform per 1ml of Trizol® Reagent  were added to the sample. This 
was centrifuged at 12000 g for 15 minutes at 4°C. T he RNA was precipitated from 
the aqueous phase by vortexing with 500µl isopropyl alcohol (isopropanol/2-
propanol/IPA) per 1ml TRIzol® Reagent. After centrifugation at 12000 g for 10 
minutes at 4°C, the supernatant was removed and the  pellet was washed with 1ml 
of 75 % ethanol (in RNase-free water) per 1ml TRIzol® Reagent. 
 
[RNA precipitate can be stored at 4°C for up to one  week or -20°C for up to one 
year]. 
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The sample was centrifuged at 7500g for 5 minutes at 4°C .The RNA was 
resuspended, incubated in a heat block at 55-60°C f or 15 minutes and placed  on 
ice.  
 
The RNA concentration was measured on (either a nano or pico depending upon 
the amount of DNA) Nanodrop ND-1000 and evaluate RNA quality on Agilent 2100 
Bioanalyser. 
 
**TRIzol® Reagent  
TRIzol® Reagent is a ready-to-use reagent, designed to isolate high quality total 
RNA (as well as DNA and proteins) from cell and tissue samples of human, 
animal, plant, yeast, or bacterial origin, within one hour. TRIzol® Reagent is a 
monophasic solution of phenol, guanidine isothiocyanate, and other proprietary 
components which facilitate the isolation of a variety of RNA species of large or 
small molecular size. TRIzol® Reagent maintains the integrity of the RNA due to 
highly effective inhibition of RNase activity while disrupting cells and dissolving cell 
components during sample homogenization.  
. 
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2.2 RNA Quality 
  
2.2.1 Nanodrop  
 
There are three quality controls that are performed on isolated RNA. One is 
to determine the quantity of RNA that has been isolated, the second is the purity of 
RNA that has been isolated and the third is the integrity of the RNA that has been 
isolated: 
 
 Measuring the Quantity of RNA using the Nanodrop 
 RNA quality control using the Agilent's 2100 Bioanalyzer 
 
Nanodrop 
The Nanodrop is a spectrophotometer that measures 1 µl samples with high 
accuracy and reproducibility. The full spectrum (220nm-750nm) 
spectrophotometer utilizes a patented sample retention technology  that employs 
surface tension alone to hold the sample in place.  This eliminates the need for 
cumbersome cuvettes  and other sample containment devices and allows for clean 
up in seconds.   
 
 
2.2.2 Agilent 2100 Bioanalyzer  
 
Agilent's 2100 Bioanalyzer uses a lab on a chip approach to perform capillary 
electrophoresis and uses a fluorescent dye that binds to RNA to determine both 
RNA concentration and integrity. The electrophoretic analysis on the chip is based 
on traditional gel electrophoresis principles that have been transferred to a chip 
format. 
Charged biomolecules like DNA or RNA are electrophoretically driven by a 
voltage  gradient, similar to slab gel electrophoresis. Because of a constant mass-
to-charge  ratio and the presence of a sieving polymer matrix, the molecules are 
separated by  size. Smaller fragments are migrating faster than larger ones. Dye 
molecules  intercalate into RNA strands and these complexes are detected by 
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laser-induced fluorescence. Data is translated into gel-like images (bands) and 
electropherograms (peaks). 
The Bioanalyzer electropherogram of total RNA shows two distinct ribosomal 
peaks corresponding to either18S and 28S for eukaryotic RNA or 16S and 23S for  
prokaryotic RNA and a relatively flat baseline between the 5S and 18S 
ribosomal peaks. In general, when analyzing good quality RNA, the height of the 
28S rRNA peak should be at least twice that of the 18S rRNA peak. For perfect 
quality RNA we indeed find ratios over 2 with the Bioanalyzer. However, almost 
exclusively RNA isolated from cell culture samples results in 28S/18S ratios larger 
than 2.  
Although the 28S/18S rRNA ratio is a reasonable way to estimate RNA integrity, it 
is not ideal and in particular in the context of the Bioanalyzer, which does not run 
under denaturing conditions sometimes the ratios do not reflect the exact level of 
RNA degradation. Besides the ratio of the 18S to 28S ribosomal RNAs, Agilent 
has introduced a software algorithm that takes the entire electrophoretic trace into  
account to help scientists estimate the integrity of total RNA samples. The RNA 
Integrity Number (RIN) software algorithm allows the classification of total RNA, 
based on a numbering system from 1 to 10, with 1 being the most degraded and 
10 being the most intact. 
It is important to realize that we assume that the integrity of the rRNA 
species provides a good indication for the integrity of the mRNA species, which is 
most of the time the RNA species that we are interested in. Although this is a 
reasonable assumption, it is by no means a fact. 
For every type of quantitative analysis,  performing experiments with RNA with a 
RIN below 6 should be done with caution.  Specially, if one would be using freshly 
harvested cultured cells or freshly harvested  tissue from a laboratory animal, the 
RIN should be definitely higher that 7.5-8 otherwise there was a problem with the 
way the RNA extraction procedure was performed. 
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2.3 Real Time PCR  
 
2.3.1 Introduction   
                                        
Real-time Polymerase Chain Reaction (PCR) is the ability to monitor the progress 
of the PCR as it occurs. Data is therefore collected throughout the PCR process, 
rather than at the end of the PCR. This completely revolutionizes the way one 
approaches PCR-based quantitation of DNA and RNA. In real-time PCR, reactions 
are characterized by the point in time during cycling when amplification of a target 
is first detected rather than the amount of target accumulated after a fixed number 
of cycles. The higher the starting copy number of the nucleic acid target, the 
sooner a significant increase in fluorescence is observed. In contrast, an endpoint 
assay (also called a “plate read assay”) measures the amount of accumulated 
PCR product at the end of the PCR cycle. 
 
TaqMan Gene Expression Assays 
In this project we used TaqMan® Gene Expression Assays of Applied Biosystem:  
 Bex1 ID: Hs00218464_m1 (_m means that an assay whose probe spans 
an exon-exon junction of the associated genes and will not detect genomic 
DNA). 
 Bex2 ID: Hs00607718_g1 (_g means that An assay whose probe spans an 
exon-exon junction, but the assay may detect genomic DNA if present in 
the sample). 
TaqMan® Gene Expression Assays are biologically informative, pre-formulated 
gene expression assays used for rapid, reliable detection and quantification of 
human, mouse and rat mRNA transcripts. These assays have been designed from 
the annotation of genes from both the public sequence databases and Celera 
Genomics. Each assay contains pre-formulated primers and TaqMan® probes in a 
20X concentration. Each tube supports 250 reactions at a 20 µL reaction volume 
or 100 reactions at a 50µL reaction volume. The TaqMan® Gene Expression 
Assays are designed to be used in two-step RT-PCR. 
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Step Process 
1. An oligonucleotide probe is constructed containing a reporter fluorescent 
dye on the 5´ end and a quencher dye on the 3´ end. While the probe is 
intact, the proximity of the quencher dye greatly reduces the fluorescence 
emitted by the reporter dye by fluorescence resonance energy transfer 
(FRET) through space. 
2. If the target sequence is present, the probe anneals downstream from one 
of the primer sites and is cleaved by the 5´ nuclease activity of Taq DNA 
polymerase as this primer is extended. 
3. This cleavage of the probe: 
 Separates the reporter dye from the quencher dye, increasing the 
reporter dye signal. 
 Removes the probe from the target strand, allowing primer extension 
to continue to the end of the template strand. Thus, inclusion of the 
probe does not inhibitthe overall PCR process. 
4. Additional reporter dye molecules are cleaved from their respective probes 
with each cycle, resulting in an increase in fluorescence intensity 
proportional to the amount of amplicon produced. 
One of the most important steps in relative quantitation experimental design is the 
selection of an appropriate endogenous control. Normalization to an endogenous 
control (often referred to as a housekeeping gene) allows you to correct results 
that can be skewed by differing amounts of input nucleic acid template. Any gene 
shown to be expressed at the same level in all study samples can potentially be 
used as an endogenous control.  
 
 
2.3.2 Preliminary Real Time PCR  
 
RNA concentration of the cell lines was analyzed on Nanodrop ND-1000 for cell 
lines: WRL68, SK-HEP, HEPG2, Chang, HUH7 and human livers: HL28 (healthy), 
HL42 (paracetamol), HL50 (cyste).  
It was reverse transcribed 1 ug RNA from each cell line to cDNA using Applied 
Biosystems High-Capacity cDNA Reverse Transcription Kit # 4368813 [RT: HL50 
(cyste), WRL68]. 
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                          X1     X6             ÷RT (X3) 
10x RT buffer:              2 µl.     12 µl          6 µl 
25x dNTP mix (100 mM): 0,8 µl.     4,8 µl         2,4 µl 
10x RT Random Primers: 2 µl.     12 µl          6 µl 
Multiscribe Revers Trans.: 1 µl.     6 µl           ÷ 
RNase Inhibitor:             1 µl.     6 µl           3 µl 
Nuclease Free H2O:             3,2 µl.     19,2 µl       12,6 µl 
Total:                         10 µl.     60 µl. 30 µl. 
 
10 µl were portioned into each of 5 Biometra tubes, added 1 ug RNA + RNase free 
H2O (total 10 µl) to each tube and performed reverse transcription on Biometra 
Thermoblock. 
 
 
Program 36: Step 1; 25 °C, 10 min, Step 2; 37 °C, 120 min, Step  3; 85 °C, 5                    
   seconds, Step 4; 4 °C, ∞. 
 
 
It was performed Real Time PCR on ABI 7300. 
Bex1:                                                       Master cocktail (x11) 
2x TaqMan PCR Master Mix:               25 µl  275 µl 
20x BEX1 TaqMan Gene Expression Assay: 2,5 µl  27,5 µl 
RNase free H2O:                                    19,5 µl  214,5 µl 
Total:                                                 47 µl.   517 µl.  
 
 
Bex2:             Master cocktail (x11)  
2x TaqMan PCR Master Mix:                                   25 µl  275 µl 
20x BEX2 TaqMan Gene Expression Assay: 2,5 µl  27,5 µl 
RNase free H2O:                                                     19,5 µl             214,5 µl                                  
Total:                                                 47 µl.   517 µl.  
 
 
3 µl cDNA were added to each Eppendorf tube and portioned 15 µl into each well 
of the 96-well PCR plate (running triplicates). Place 96-well plate was placed in 
ABI 7300, chosen FAM as repoter dye, ROX as passive reference dye. The Real 
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Time PCR was run with the following parameters: Step1: 95 °C for 10 min 
repetition = 1, Step 2: 95 °C for 0:15  seconds – 6 0 °C for 1 min, repetition = 
40. 
 
 
2.3.3 Real Time PCR Dilution Curves 
 
RNA concentration of the tissue was analyzed [HL42 (paracetamol intoxication of 
human liver)] on Nanodrop ND-1000 and 1 µg RNA was reverse transcribed to 
cDNA using Applied Biosystems High-Capacity cDNA Reverse Transcription   Kit 
# 4368813. 
                                              X1       X3 
10x RT buffer:                     2 µl      6 µl 
25x dNTP mix (100 mM):                    0,8 µl      2,4 µl  
10x RT Random Primers:         2 µl      6 µl  
Multiscribe Revers Trans.:         1 µl      3 µl  
RNase Inhibitor:                                1 µl      3 µl  
Nuclease Free H2O:                     3,2 µl      36,89 µl + 2,71 µl RNA  
Total:                                 10 µl      60 µl 
 
1 ug RNA + RNase free H2O (total 10 µl) were added to each tube and perform 
reverse transcription on Biometra Thermoblock. 
 
Dilution 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
(BEX1) 
8 8 8 4 4 4 2 2 2 1 1 1 
B 
(BEX1) 
0,5 0,5 0,5 0,25 0,25 0,25 0,125 0,125 0,125 0,0625 0,0625 0,0625 
C 
(BEX1) 
0,031 0,031 0,031 0,0156 0,0156 0,0156 0,0078 0,0078 0,0078 0,0039 0,0039 0,0039 
D 
(BEX1) 
0,002 0,002 0,002 0,001 0,001 0,001 0,0005 0,0005 0,0005 0,0002 0,0002 0,0002 
E 
(BEX2) 
8 8 8 4 4 4 2 2 2 1 1 1 
F 
(BEX2) 
0,5 0,5 0,5 0,25 0,25 0,25 0,125 0,125 0,125 0,0625 0,0625 0,0625 
G 
(BEX2) 
0,031 0,031 0,031 0,0156 0,0156 0,0156 0,0078 0,0078 0,0078 0,0039 0,0039 0,0039 
H 
(BEX2) 
0,002 0,002 0,002 0,001 0,001 0,001 0,0005 0,0005 0,0005 0,0002 0,0002 0,0002 
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Program 36: Step 1; 25 °C, 10 min, Step 2; 37 °C, 1 20 min, Step 3; 85 °C, 5 
seconds, Step 4; 4  °C, ∞. 
After reverse transcription it was done the cDNA dilutions with RNase-free H2O (a 
total of 16 wells). 
 
 
 
 
 
 
 
 
 
Master Mix (the solutions  are sensitive to light) 
 
  
  
 
 
 
 
 
 
 
 
It was mixed cDNA (8 µl) with Master Mix (42 µl) , started with the most diluted 
cDNA and proceeded towards the undiluted cDNA. It was transfered 15 µl from the 
solutions to a 96-well PCR plate, this is done in triplicates. The plate was placed in 
the Real-Time PCR machine [Applied Biosystems 7300 Real-Time PCR System], 
programed the software and initiated the run. 
 
 
BEX1 
                                  X1            X17 
MMx2                      25 µl            = 425 µl MMx2 
H2O:                      14,5 µl            = 246,5 µl H2O 
20xProbe/Primer:     2,5 µl            = 42,5 µl 20xProbe/Primer 
Total.vol. =            42 µl            = 714 µl for 16 samples + 1  for the pipette. 
cDNA Most diluted Dilutions 
BEX2 
                                  X1            X17 
MMx2                      25 µl            = 425 µl MMx2 
H2O:                     14,5 µl            = 246,5 µl H2O 
20xProbe/Primer:     2,5 µl            = 42,5 µl 20xProbe/Primer 
Total.vol. =            42 µl            = 714 µl for 16 samples + 1  for the pipette. 
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2.3.4 Real Time PCR on Liver Tissues 
 
After the Dilution Curves was executed the Real-Time PCR  on cDNA of 15 
different liver tissues (4 donor livers and 11 diseased livers): 
 Donor Liver HL47  
 Donor Liver HL49  
 Healthy Liver (resection) HL28  
 Healthy Liver HL33  
 Primary Biliary Cirrhosis (PBC) HL26  
 Prymary Biliary Cirrhosis (PBC) HL38  
 Primary Biliary Sclerosis (PBS) HL54  
 Sclerosing Cholangitis HL62  
 Primary Sclerosing Cholangitis (PSC) HL52  
 Adult Ductopeni-Cirrhosis? HL32  
 Alc. Sclerosis-Cirrhosis? HL36  
 Alcoholic Liver Disease HL27  
 Alcoholic Liver Disease HL44  
 Toxic Liver Disease HL43  
 Paracetamol Intoxication HL42  
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2.4 Immunohistochemistry 
 
2.4.1 Introduction  
 
Immunohistochemistry (IHC) allows the 
localization of antigens in tissue sections 
by the use of labeled antibody as specific 
reagents through antigen-antibody 
interactions that are visualized by a 
marker such as fluorescent dye, enzyme, 
radioactive element or colloidal gold.  
There are numerous immunohistochemistry methods that may be used to localize 
antigens. The selection of a suitable method should be based on parameters such 
as the type of specimen under investigation and the degree of sensitivity required. 
While using the right antibodies to target the correct antigens and amplify the 
signal is important for visualization, complete preparation of the sample is critical 
to maintain cell morphology, tissue architecture and the antigenicity of target 
epitopes. This requires proper tissue collection, fixation and sectioning. 
Paraformaldehyde is usually used with fixation. Depending on the purpose and the 
thickness of the experimental sample, either thin (about 4-40 µm) sections are 
sliced from the tissue of interest, or if the tissue is not very thick and is penetrable 
it is used whole. The slicing is usually accomplished through the use of 
a microtome, and slices are mounted on slides. "Free-floating IHC" uses slices 
that are not mounted, these slices are normally produced using a 
vibrating microtome. 
Fixation: 
Tissue preparation is the cornerstone of immunohistochemistry. To ensure the 
preservation of tissue architecture and cell morphology, prompt and adequate 
fixation is essential. However, inappropriate or prolonged fixation may significantly 
diminish the antibody binding capability. 
  
 Fig.16 Protein Bex1 in Donor Liver 
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There is no one universal fixative that is ideal for the demonstration of all antigens. 
However, in general, many antigens can be successfully demonstrated in formalin-
fixed paraffin-embedded tissue sections. The discover and development of antigen 
retrieval techniques further enhanced the use of formalin as routine fixative 
for immunohistochemistry in many research laboratories.  
  
For best results, vertebrate tissues (especially neuronal tissues) usually require 
fixation by transcardial perfusion for optimal tissue preservation. The most 
common fixatives used for immunohistochemistry are the followings: 
  
a) 4% paraformaldehyde in 0.1M phosphate buffer 
b) 2% paraformaldehyde with 0.2% picric acid in 0.1M phosphate buffer 
c) PLP fixative: 4% paraformaldehyde, 0.2% periodate and 1.2% lysine in 0.1M 
phosphate buffer 
d) 4% paraformaldehyde with 0.05% glutaraldehyde (TEM immunohistochemistry) 
e) 4% formaldehyde in phosphate buffered saline (our fixation) 
 
Some antigens will not survive even moderate amounts of aldehyde fixation. 
Under this condition, tissues should be rapidly fresh frozen in liquid nitrogen and 
cut with a cryostat without infiltrating with sucrose. The sections should be kept 
frozen at -20 C or lower until fixation with cold acetone or alcohol. After fixation, 
the sections can be processed using standard immunohistochemical staining 
protocols 
  
Sectioning: 
Since its introduction, paraffin wax has remained the most widely used embedding 
medium for diagnostic histopathology in routine histological laboratories. 
Accordingly, the largest proportion of material for immunohistochemistry is 
formalin-fixed, paraffin-embedded. Paraffin sections produce satisfactory results 
for the demonstration of majority of tissue antigens with the use of antigen retrieval 
techniques.  
  
Certain cell antigens do not survive routine fixation and paraffin embedding. So the 
use of frozen sections still remains essential for the demonstration of many 
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antigens. However, the disadvantage of frozen sections includes poor morphology, 
poor resolution at higher magnifications, special storage needed, limited 
retrospective studies and cutting difficulty over paraffin sections. 
Vibratome sections have some advantages when doing immunohistochemistry 
since the tissue is not processed through organic solvents or high heat, which can 
destroy the antigenicity. In addition, the morphology of tissue sections is not 
disrupted due to no freezing and thawing needed. Vibratome sections are often 
used for floating immunostaining, especially for pre-embedding EM 
immunohistochemistry. The disadvantage of vibratome sections is that the 
sectioning process is slow and difficult with soft and poorly fixed tissues. In 
addiction, the chatter marks or vibratome lines are often appeared in the sections. 
  
Whole Mount Preparation: 
Small blocks of tissue (less than 5 mm thick) can be processed as whole mounts. 
The advantage of whole mount preparations is that the results provide three 
dimensional information about the location of antigens without the need for 
reconstruction from sections. However, the major limitation of using whole mounts 
is antibody penetration which may not be complete in the tissue, resulting in 
uneven staining or false negative staining. So Triton X-100 or saponin treatment 
are used routinely for whole mount immunohistochemistry to enhance penetration 
of the antibody. 
The antibodies used for specific detection can be polyclonal or monoclonal. 
Polyclonal antibodies are made by injecting animals with peptide Ag and, after a 
secondary immune response is stimulated, isolating antibodies from whole serum. 
Thus, polyclonal antibodies are a heterogeneous mix of antibodies that recognize 
several epitopes. Monoclonal antibodies show specificity for a single epitope and 
are therefore considered more specific to the target antigen than polyclonal 
antibodies. For IHC detection strategies, antibodies are classified as primary or 
secondary reagents. Primary antibodies are raised against an antigen of interest 
and are typically unconjugated (unlabelled), while secondary antibodies are raised 
against immunoglobulins of the primary antibody species. The secondary antibody 
is usually conjugated to a linker molecule, such as biotin, that then recruits 
reporter molecules, or the secondary antibody is directly bound to the reporter 
molecule itself. 
 Reporter molecules vary based on the nature of the detection method, and the 
most popular methods of detection are with enzyme
chromogenic and fluorescent detection
an enzyme label is reacted with a substrate to yield an intensely colored product 
that can be analyzed with an ordinary light microsc
substrates is extensive,
peroxidase (HRP) are the two enzymes used most extensively as labels for protein 
detection. An array of chromogenic, fluorogenic and chemiluminescent substrates 
is available for use with either enzyme, including
produce a brown or purple staining, respectively, wherever the enzymes are 
bound. Reaction with DAB can be enhanced using
purple/black staining. Fluorescent reporters 
IHC detection and traditionally include
derivatives, including the Alexa Fluors and Dylight Fluors, show similar enhanced 
performance but vary in price. For chromogenic and fluorescent detection 
methods, densitometric analysis of the signal can provide semi
quantitative data, respectively, to correlate the level of reporter signal to the level 
of protein expression or localization.
 
The direct method of immunohistochemical staining uses one labelled antibody, 
which binds directly to the antigen being stained for.
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- and fluorophore
, respectively. With chromogenic reporters, 
ope. While the list of enzyme 
 Alkaline phosphatase (AP) and
 DAB or
 nickel, producing a deep 
are small, organic molecules used for 
 FITC, TRITC and AMCA, while commercial 
 
 
 
 
Fig.17 The direct method of immunohistochemical 
staining uses one labelled antibody, which binds 
directly to the antigen being stained for.
Fig.18 The indirect method of immunohistochemical 
staining uses one antibody against the antigen 
probed for, and a second, labelled, antibody against 
the first. 
-mediated 
 horseradish 
 BCIP/NBT, which 
- and fully-
 
being 
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The indirect method of immunohistochemical staining uses one antibody against 
the antigen being probed for, and a second, labeled, antibody against the first. 
After immunohistochemical staining of the target antigen, a second stain is often 
applied to provide contrast that helps the primary stain stand out. Many of these 
stains show specificity for discrete cellular compartments or antigens, while others 
will stain the whole cell. Both chromogenic and fluorescent dyes are available for 
IHC to provide a vast array of reagents to fit every experimental design, and 
include: hematoxylin, Hoechst stain and DAPI are commonly used. 
 
 
2.4.2 Antibody Optimization for DAB Histochemistry 
 
Bex1 and CK19 optimization 
The sections of human liver (healthy and pathological) were deparafinized, 
incubated in 3% H2O2 / methanol to block endogenous peroxidise activity and 
rehydrate in ethanol. The sections were boiled in different antigen retrieval buffers 
for 10min or 10+10min: 
 Do nothing 
 Dako citrate retrieval [ DakoCytomation Target Retrieval Solution, pH6, 10x 
concentrate, RF S1699 ]  
 Dako high pH retrieval [ DakoCytomation Target Retrieval Solution, high pH, 
10x concentrate, RF S3307 ]  
 Dako pH 9 retrieval [ DakoCytomation Target Retrieval Solution, high pH, 10x 
concentrate, RF S2367 ] 
 
The sections were washed in TBST* and the protein blocked with Serum Free 
Blocking Medium in a moisture chamber for 20 min at RT (Protein Block, Serum-
Free, Ready-To-Use, Ref X0909, DakoCytomation, Glostrup, Denmark). 
The sections were incubated for 1 h at room temperature (RT) or at 4°C overnight, 
in a moisture chamber, with the primary antibodies diluted in TBSB**. The 
secondary antibodies were applied for 30min at RT, the sections were incubated in 
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diaminobenzidine (DAB) for 10 min (exactly) in a moisture chamber, 
counterstained in Mayers haematoxylin for 7 min or 15min, dehydrated and 
mounted in Eukitt. 
 
 
Bex 1 antibody dilutions:                       Sections of human liver:   
 
 
 
 
 
CK19 antibody dilutions: 
1:50 
1:100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1:100 
1:1000 
1:1500 
1:2000 
1:3000 
1:15000 
1:50000 
1:100000 
1:150000 
Abcam Ab 
Margolis Ab 
 Donor Liver HL49  
 Paracetamol Intoxication HL42  
 Primary Biliary Cirrhosis (PBC) 
 Primary Sclerosing Cholangitis (PSC)  
 Large Duct Obstruction (LDO) 
 Steatohepatitis  
 Toxic Hepatitis 
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Primary antibody: 
• Bex1, rabbit, # ab69032, Abcam plc, 330 CambridgeScience Park 
Cambridge, CB4 0FL, UK  
• Polyclonal rabbit anti-Bex1 antibody, Frank L. Margolis Lab, Department of 
Anatomy and Neurobiology, University of Maryland, School of Medicine, 
HSF II S203, 20 Penn Street, Baltimore, Maryland 21201. 
• CK19, Monoclonal Mouse, Anti-Human Cytokeratin 19, Clone RCK108, 
Kode nr. M 0888, Dako, Glostrup, Denmark. 
 
Secondary antibody: 
• Envision + R system. Labelled Polymer-HRP anti-rabbit. REF K4002. 
Dakocytomation, 6392 Via Real, Carpinteria, CA 93013, USA. 
• Envision + R system. Labelled Polymer-HRP anti-mouse. REF K4000. 
Dakocytomation, 6392 Via Real, Carpinteria, CA 93013, USA. 
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Recommended dilutions 
ICC/IF: 1/200.  
IHC-P: 1/300 - 1/3000. Antigen 
retrieval is recommended.  
IHC-Fr: 1/300 - 1/3000.  
WB: 1/300 - 1/3000. This 
antibody has been tested in 
Western blot against the 
recombinant peptide used as an 
immunogen. We have no data on 
detection of endogenous protein. 
Predicted molecular weight: 14 
kDa.  
 
 
Not yet tested in other 
applications. 
Optimal dilutions/concentrations 
should be determined by the end 
user. 
Cellular localization  Cytoplasmic and Nuclear 
Research areas  Neuroscience >> Neurology process >> Neuroregeneration >>Neuroregeneration 
Cancer >> Oncoproteins/suppressors >> Tumor suppressors >> Other 
Neuroscience >> Neurology process >> Neurogenesis 
Signal Transduction >> Adapters >> Cytoplasmic 
Neuroscience >> Neurotransmission >> Intracellular Signaling >> Adapters 
Relevance  Bex1 is a signaling adapter molecule involved in p75NTR/NGFR signaling. It is 
thought to play a role in cell cycle progression and neuronal differentiation. Bex1 
inhibits neuronal differentiation in response to nerve growth factor (NGF). Bex1 has 
also been implicated as a tumor suppressor 
  Alternative names Bex1 antibody (ab69032) 
Database links  The links below go to external sites and will open in a new browser window 
Entrez 
Gene 
    55859    
(Human) 
 
SwissProt    Q9HBH7    
(Human) 
 
 
Raised in  Rabbit 
Clonality  Polyclonal 
Isotype  IgG 
Purity  Whole antiserum 
Storage buffer  Preservative: None 
Constituents: Whole serum 
Form  Liquid 
Concentration  Concentration not determined  
Storage instructions  Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C (add glycerol to a final 
volume of 40% for extra stability). Avoid repeated freeze / thaw cycles. 
Information about ab69032 on abcam website (Bex1 antibody) 
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Information about Bex1 antibody of Frank L. Margolis Lab 
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Buffer list: 
10X TBS (0.5 M TRIS, 1.5 M NaCl), 2 L 
121.2 g TRIS 
175.2 g NaCl 
Dissolve in MQ water. Adjust pH to pH 7.4 for a total volume of 2 liter. When 
making 1xTBS adjust new solution to pH 7.4 
 
*1xTBS / 1% Triton X-100 (TBST), pH 7.4, 5 L (0.05 M Tris, 0.15 M NaCl, 1% 
Triton) 
500 ml 10 x TBS 
50 g Triton X-100 
Add MQ water and adjust solution to pH 7.4 for a total volume of 5 liter. Triton x-
100 dissolves slowly and foams – therefore start the TBST manufacturing process 
with dissolving this compound.   
 
**1xTBS / 0.25% BSA (TBSB), pH 7.4  
300 ml 1x TBS, pH 7.4 
0.75 g BSA 
Steril-filtrate and aliquote into 15 ml tubes. Stored by -20 °C.  
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2.4.3 Antibody Optimization for Immunofluorescence 
 
Frozen sections [HL49 (Donor Liver) and HL54 (Primary Biliary Cirrhosis), 10 µm] 
were fixed in ice cold acetone (at  -20°C) for 20 m in, washed in TBS/1% triton X-
100 (TBST) and incubated in humid chamber for 20 min at RT in serum free 
blocking solution. The primary antibodies were diluited in TBSB or TBSB / 0,2% 
TX and incubated in a humid chamber for 1 hour at RT. The second antibodies 
were incubated for 1 hour at RT (it is important to work in the dark). The sections 
were mounted in DAPI containing mounting medium. 
 
 
Primary antibodies 
• Bex1, rabbit, # ab69032, Abcam plc, 330 CambridgeScience Park 
Cambridge, CB4 0FL, UK. 
Dilution: 1-100 
• Polyclonal rabbit anti-Bex1 antibody, Frank L. Margolis Lab, Department of 
Anatomy and Neurobiology, University of Maryland, School of Medicine, 
HSF II S203, 20 Penn Street, Baltimore, Maryland 21201. 
Dilution: 1-2000, 1-20000 
• CK7, Monoclonal Mouse, Anti-Human Cytokeratin 7, Clone OV-TL 12/30, 
Kode nr. M 7018, Glostrup, Denmark. 
Dilution: 1-50 
 
Secondary antibodies 
• Alexa Fluor, A11037, 594, goat anti rabbit, Invitrogen, Ltd. 3 Fountain Drive, 
Inchinnan Business Park, Paisley PA4 9RF, UK 
Dilution: 1-400 
• Alexa Fluor, A11029, 488, goat anti mouse, Invitrogen, Ltd. 3 Fountain 
Drive, Inchinnan Business Park, Paisley PA4 9RF, UK 
Dilution: 1-400 
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2.4.4 Bex1 and CK19 Detection in Different Liver Tissues  
 
The sections of human liver (healthy and pathological) were deparafinized, 
incubated in 3% H2O2 / methanol to block endogenous peroxidise activity and 
rehydrated in ethanol. The sections were boiled in Dako pH 9 antigen retrieval 
buffer [ DakoCytomation Target Retrieval Solution, high pH, 10x concentrate, RF 
S2367 ] for  10+10min. The sections were washed in TBST and the protein 
blocked with Serum Free Blocking Medium in a moisture chamber for 20 min at RT 
(Protein Block, Serum-Free, Ready-To-Use, Ref X0909, DakoCytomation, 
Glostrup, Denmark). The sections were incubated at 4°C overnight , in a moisture 
chamber, with the primary antibodies diluted in TBSB. The secondary antibodies 
were applied for 30min at RT, the sections were incubated in diaminobenzidine 
(DAB) for 10 min (exactly) in a moisture chamber, counterstained in Mayers 
haematoxylin for 15min, dehydrated and mounted in Eukitt. 
 
Primary antibody: 
• Polyclonal rabbit anti-Bex1 antibody, Frank L. Margolis Lab, Department of 
Anatomy and Neurobiology, University of Maryland, School of Medicine, 
HSF II S203, 20 Penn Street, Baltimore, Maryland 21201. 
Dilution: 1-1500 
• CK19, Monoclonal Mouse, Anti-Human Cytokeratin 19, Clone RCK108, 
Kode nr. M 0888, Dako, Glostrup, Denmark. 
Dilution: 1-50 
 
Secondary antibody: 
• Envision + R system. Labelled Polymer-HRP anti-rabbit. REF K4002. 
Dakocytomation, 6392 Via Real, Carpinteria, CA 93013, USA. 
• Envision + R system. Labelled Polymer-HRP anti-mouse. REF K4000. 
Dakocytomation, 6392 Via Real, Carpinteria, CA 93013, USA. 
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Sections of human liver: 
 
 Donor Liver  
 Primary Biliary Cirrhosis (PBC) 
 Primary Sclerosing Cholangitis (PSC) 
 Large Duct Obstruction (LDO) 
 Steatohepatitis  
 Toxic Hepatitis 
 Hepatitis B (HBV) 
 Hepatitis C (HCV) 
  
- 53 - 
 
2.5 Maintenance of Cancer Cell Lines 
 
Cell lines: 
 
 HUH7 (It is a well differentiated hepatocyte derived cellular carcinoma cell 
line that was originally taken from a liver tumor in a 57-year-old Japanese 
male in 1982. The line was established by Nakabayshi, H. and Sato, J.) 
 
 HEPG2 
 WRL68 
 SK-HEP1 
 
The frozen cells were removed from -80°C freezer, a dded media [DMEM + 
GlutaMAX (450ml), 10% FBS (50ml), Gentamicin (2.5ml)] and centrifuged at 
1200 RPM for 3 min RT. The pellet was isolated, added media, transfered into the 
T-25 cell culture flasks and these were put in the incubator at 37°C with humidified 
atmosphere of 5% CO2. The cells were washed with PBS, splitted with Trypsin and 
put in T-75 flasks. 
 
The cells were trypsinized, counted and diluted in growth media to a plating 
density of 15-75% confluency (depending upon growth rate of cells and 
requirements of end point assay). It was plated 200.000 cells Huh7 cells per 
well in 2ml media, 2 x 6 well plates, 3 wells / plate. The cells were incubated at 
37°C with 5% CO 2 overnight. 
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2.6 Knockdown with siRNA 
 
2.6.1 Introduction 
 
Over the years, gene silencing 
by RNAi has relied heavily on 
the use of cationic lipid-based 
delivery reagents for transfecting 
cells with small interfering RNAs 
(siRNAs). In many cases, lipid-
based transfection is sufficient 
and provides efficient levels of 
gene knockdown. Yet in a 
significant fraction of cases, cells 
are either refractory to 
lipidmediated delivery of siRNAs 
or aversely sensitive to the 
presence of lipids. 
 
 
Dharmacon® Accell® siRNA 
The Accell siRNA product line represents a recently develope  technology that 
promotes delivery of siRNA independent of viral vectors or lipid-based transfection 
reagents (also referred to as “passive delivery”) to virtually any cell type. 
 
This novel delivery technology permits gene silencing with minimal off-target 
events (as assessed by genome-wide profiling), has limited repercussions on cell 
viability, and  triggers a negligible innate immune response. Thus, unlike 
electroporation, which is historically the first alternative delivery method for cells 
found to be averse to lipid based  transfection  reagents, Accell siRNA can be 
employed without significant effects on cell physiology.  
Fig.19 Experimental workflow for Accell siRNA 
mediated gene silencing and detection of mRNA 
knockdown. 
- 55 - 
 
Over the course of investigations, it is often necessary to knock down gene 
expression for estende periods of time to accurately assess the contribution of a 
particolar protein to a given biological event. Long-term reduction of gene 
expression can be problematic, particularly in cases where there are large 
intracellular reservoirs of the target or the half-life of the protein is drawn out. In 
some instances, researchers have attempate multiple, consecutive lipid-mediated 
transfections of siRNAs into cultured cells. Unfortunately, this approach is 
frequently cytotoxic and can induce brief (24-72 hrs) changes in the state of the 
innate immune response. To overcome these barriers, DNA-mediated RNAi, 
commonly exploiting viral delivery platforms, has been adopted. This approach 
can be successful, but is costly and requie significant development time. 
Each experiment should include the following samples in triplicate: 
1. Untreated cells (cells growing in Accell medium or any other medium used for 
Accell siRNA delivery) 
2. Positive control siRNA (targeting an endogenous or reporter gene) 
3. Negative control siRNA (non-targeting siRNA control) 
4. The desired test siRNA 
Optimal cell densities will vary with growth characteristics of specific cell types. It is 
recommended to assess the growth rate of the cells in Accell delivery media prior 
to carrying out Accell siRNA silencing experiments. 
 
 
2.6.2 Transfection of Huh7 Cell Line 
 
 Plate 1, 3x well: - transfection with siRNA Bex1 SMART Accell (50nm, 
Thermo Scientific) 
 Plate 2, 3x well: - control (no transfection, untreated cells) 
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5X siRNA buffer (Cat.# B-002000-UB-100) was diluted to 1X siRNA buffer (100µ + 
400µl DEPC-treated Water). 500µl 1x siRNA buffer were added to siRNA BEX1 
(50nmol) to have 100 µM siRNA solution. 120µl of this solution were mixed with 
12mL Accell delivery media (Cat.# B-005000) with final concentration 1µM Accell 
siRNA per well in a 6-well plate. The cells were incubated at 37ºC with 5% CO2 for 
72 hours. 
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2.7 Protein Harvest  
 
Before harvest: 
500µL Buffer A* were mixed with 50µL Protease inhibitor cocktail (p8340) 
(Sigma-Aldrich) 
[It is recommended to use 1:10 every 1x108 cells/mL. There is ca. 8x105 cells/mL 
in a 10cm dish. For this make a 125x dilution of the cocktail mix (8µL protease 
inhibitor cocktail + 992µL MilliQ) (stored: -20°C f reezer). Of this add  1:10  to 
Buffer A (50µL cocktail : 500µL Buffer A)]. 
The cells were washed in PBS, added the solution with 500µL Buffer A*  and 50µL 
Protease inhibitor cocktail (p8340) (Sigma-Aldrich). The scraped cells were 
freezed – thawed for lysis, centrifugated at 20.000g at 4°C. The supernatant can 
be store at -20°C. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protease Inhibitor (in 300 µl) 
3 ml PMSF 
1.5 µl APO 
1.5 µl LEU 
*Buffer A: 
 
1ml, 1M Hepes /0,2383g HEPES 
0,0757 g KCL 
0,0312g MgCl2 
11,67g sucrose 
20ml 50% glycerol 
100µl 100% Triton X-100 
 
1. Add 50ml Milli-Q. 
2. pH should be 7,93. (adjusted 
with 5M HCl and NaOH). 
3. Fill up till 100ml with Milli-Q. 
4. Aliquot and store at -20°C.  
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2.8  Bradford Protein Assay 
 
2.8.1 Introduction  
 
The Bradford assay, a colorimetric protein assay, is based on an absorbance shift 
of the dye Coomassie Brilliant Blue G-250. In the acidic environment of the 
reagent, protein binds to the Coomassie dye. This results in a spectral shift from 
the reddish/brown form of the dye 
(absorbance maximum at 465nm) to 
the blue form of the dye (absorbance 
maximum at 610nm). The difference 
between the two forms of the dye is 
greatest at 595nm, so that is the 
optimal wavelength to measure the 
blue color from the Coomassie dye-
protein complex. If desired, the blue 
color can be measured at any 
wavelength between 575nm and 
615nm. At the two extremes (575nm 
and 615nm) there is a loss of about 
10% in the measured amount of color (absorbance) compared to that obtained at 
595nm.  
Development of color in Bradford protein assays is associated with the presence 
of certain basic amino acids (primarily arginine, lysine and histidine) in the protein. 
Van der Waals forces and hydrophobic interactions also participate in the binding 
of the dye by protein. The number of Coomassie dye ligands bound to each 
protein molecule is approximately proportional to the number of positive charges 
found on the protein. Free amino acids, peptides and low molecular weight 
proteins do not produce color with Coomassie dye reagents. In general, the mass 
of a peptide or protein must be at least 3000 daltons to be detectable with this 
reagent. 
Coomassie dye binding assays are the fastest and easiest to perform of all protein 
assays. The assay is performed at room temperature and no special equipment is 
Fig.20 Coomassie Brilliant Blue 
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required. Standard and unknown samples are added to tubes containing 
preformulated Coomassie assay reagent and the resultant blue color is measured 
at 595nm following a short room temperature incubation. The Coomassie dye-
containing protein assays are compatible with most salts, solvents, buffers, thiols, 
reducing substances and metal chelating agents encountered in protein samples. 
The main disadvantage of Coomassie based protein assays is their incompatibility 
with surfactants at concentrations routinely used to solubilize membrane proteins. 
In general, the presence of a surfactant in the sample, even at low concentrations, 
causes precipitation of the reagent. In addition, the Coomassie dye reagent is 
highly acidic, so proteins with poor acid-solubility cannot be assayed with this 
reagent.  
 
 
2.8.2 Protein Concentration Measurement  
 
PIERCE Coomassie Plus – The Better BradfordTM Assay Kit. It was set up a 
standard set with BSA (2,0 mg/ml) diluted with 1% Buffer A. It was made 3 
dilutions 1:100 and 1:300 and 1:1000 with milli-Q. 
 
 
 
 
 
 
 
 
990 µl 500 µl 500 µl 500 µl 750 µl 500 µl 1% Buffer A 
500 µl 500 µl 500 µl 500 µl 
10 µl BSA 2mg/ml 
  
 
 
All dilutions were measured in triplo. 150µl 
standardset and 150 µl of Coomassie Blue Plus reagens
wells. Absorbance was
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
990 µl 800 µl 
10 µl protein 
400 µl 300
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was added per well of the BSA 
 (RT) was
 measured at 595 nm with a spectrophotometer.
700 µl Milli-Q 
 µl 
 added to all 
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2.9 Western Blot 
 
2.9.1 Introduction 
 
The term "blotting" refers to the transfer of biological samples from a gel to a 
membrane and their subsequent detection on the surface of the membrane. The 
specificity of the antibody-antigen interaction enables a target protein to be 
identified in the midst of a complex protein mixture 
The first step in a Western blotting procedure is to separate the macromolecules 
using gel electrophoresis. After electrophoresis, the separated molecules are 
transferred or blotted onto a second matrix, generally a nitrocellulose or 
polyvinylidene difluoride (PVDF) membrane. Next, the membrane is blocked to 
prevent any nonspecific binding of antibodies to the surface of the membrane. 
Most commonly, the transferred protein is complexed with an enzyme-labeled 
antibody as a probe. An appropriate substrate is then added to the enzyme and 
together they produce a detectable product such as a chromogenic precipitate on 
the membrane for colorimetric detection. The most sensitive detection methods 
use a chemiluminescent substrate that, when combined with the enzyme, 
produces light as a byproduct. The light output can be captured using film, a CCD 
camera or a phosphorimager that is designed for chemiluminescent detection. 
Alternatively, fluorescently tagged antibodies can be used, which are directly 
detected with the aid of a fluorescence imaging system. Whatever system is used, 
the intensity of the signal should correlate with the abundance of the antigen on 
the membrane. 
Detailed procedures for detection of a Western blot vary widely. One common 
variation involves direct vs. indirect detection. With the direct detection method, 
the primary antibody that is used to detect an antigen on the blot is labeled with an 
enzyme or fluorescent dye. This detection method is not widely used as most 
researchers prefer the indirect detection method for a variety of reasons. In the 
indirect detection method, a primary antibody is added first to bind to the antigen. 
This is followed by a labeled secondary antibody that is directed against the 
primary antibody. Labels include biotin, fluorescent probes such as fluorescein or 
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rhodamine, and enzyme conjugates such as horseradish peroxidase or alkaline 
phosphatase. The indirect method offers many advantages over the direct method. 
 
 
2.9.2 Western Blot Esecution 
 
Product Cat.nr. Company 
NuPAGE MES SDS Buffer Kit NP0060 Invitrogen 
NuPAGE Transfer Buffer 20x NP006-1 Invitrogen 
NuPAGE Novex Bis-Tris Mini 
gels 4-12% 
NP0323BOX Invitrogen 
Western Lightning® Plus-ECL 
 
NEL103001EA 
 
Perkin Elmer 
See Blue Plus2 Pre-stained 
Marker 
LC5925 Invitrogen 
 
 
Sample preparation 
 
 Huh7+Bex1 Huh7 (Control) 
Sample (12µg) 6,6µl* 9,1µl 
4x Sample 
buffer(kit) 
3,75µl 3,75µl 
10x Reducing 
Agent (kit) 
1,5µl 1,5µl 
H2O  3,15µl 0,65µl 
 
*protein concentration Huh7+Bex1 [1,82mg/ml],  Huh7(control)[1,32mg/ml] 
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Gel preparetion 
 
In the XCell SureLock™ Mini-Cell system(Invitrogen) was put  the MES running 
Buffer(1x) [ 40ml 20x running buffer(kit) plus 760ml H2O] plus antioxidant. The 
comb was removed and the wells were rinsed with running buffer. The samples 
and 5µl of Marker were loaded and in the rest of wells were filled with 3,75µl 
sample buffer + 11,25µl H2O. The gel was run at 200V for 50 min. 
 
Gel load:   M    H2O    H2O    H2O    Bex1    Control    M 
 
The  2 sponge pads, 4 filterpapers and the nitrocellulose membrane were pre 
wetted in 1x transfer buffer*. 
 
 
 
 
 
 
 
Set up the Xcell II Blot Module (Invitrogen) [Blot Sandwich] 
 
The wells were cut off and with the pre-soaked filterpapers, the 2 sponge pads, the 
membrane was formed the Blot Sandwich and the gel is closest to the cathode 
plate (see figure below).  
 
 
       
 
 
-Sponge pad 
-Sponge pad 
 
-Filter paper 
-Membrane 
-Gel 
-Filter paper 
 
 
-Sponge pad 
-Sponge pad 
 
Cathode Core (-) 
*1x Transfer Buffer: 
- 25ml 20x transfer buffer(kit) 
- 0,5 ml antioxidant (kit) 
- 50 ml methanol ( for 1 gel) 
- 424,5 ml H2O 
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The gel membrane sandwich and blotting pads were positioned in the cathode 
core of the XCell II™ Blot Module to fit horizontally across the bottom of the unit. 
The sandwich was covered with transfer buffer and 600ml of deionized H2O was 
added to the lower chamber. It was blotted at 30V for 1 hour  (start with 220mA 
and end with 180 mA). 
[The membrane can be stored from this time on wrapped in plastic foil at 4⁰C] 
 
 
Immunodetection 
  
[Bex1 antibody (Margolis, ~23kDa), host: rabbit. 1:20000 WB] 
The membrane was blocked 1 hour in 20ml 5% skimmed milk powder in TBST, 
incubated membrane 1 hour with the primary antibody (anti-Bex1:   diluted 
1:20000 in TBS-T, 0,5µl in 10ml) and 1 hour with the secondary antibody (rabbit 
anti Ab HRP diluted 1:5000 in TBS-T , 1µl in 5ml). 
 
 
Detection with Western Lightning Plus-ECL 
 
The Luminol Reagent was mixed 1:1with the oxidizing reagent  (500µl +500µl), the 
membrane - protein was faced down on the mixture and wrapped in cling film. 
Pictures were taken with LAS 1000 with Chemiluminescence (high intensity 
exposure, start with 1-5 seconds and longer depending on detection). 
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3 RESULTS  
 
3.1 Nanodrop Results 
 
 
ng/µl (Nanodrop) Take out (µl) (1000/nanodrop ng) 
add water RNA 
free to 10 µl 
total 
volume µl 
WRL68 333,9 2,99 7,01 10 
SK-HEP1 340,01 2,94 7,06 10 
Chang 365,6 2,74 7,26 10 
HEPG2 333,3 3,00 7,00 10 
HUH7 338,4 2,96 7,04 10 
HL50 634,8 1,58 8,42 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ng/ul (Nanodrop) 260/280 260/230 
HL42 1107 1,91  0,76 
Table 1 
Table 2 
 3.2 Agilent 2100 Bioanalyzer Results
 
 
 
Fig.21 
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Chart1 
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Chart 2 
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3.3 Preliminary Real Time PCR Results  
 
 
Document Name: BEX1-BEX2 07/04/2011 
 
Plate Type: Absolute Quantification 
User: ICMM8011 
Document Information 
Operator: ICMM8011 
Run Date: Friday  April 08  2011 12:48:13 
Last Modified: Friday  April 08  2011 14:10:21 
Instrument Type: Applied Biosystems 7300 Real-Time PCR System 
Comments: 
SDS v1.3.1 
Thermal Cycler Profile 
Stage Repetitions Temperature Time Ramp Rate 
Auto 
Increment 
1 1 95.0 °C 10:00 Auto 
2 40 95.0 °C 00:15 Auto 
60.0 °C 01:00 Auto 
Standard 7300 Mode 
Data Collection :  Stage 2 Step 1 
PCR Volume: 15 µL 
Well Sample Name Detector Task Ct StdDev Ct 
A1 WRL68 Bex1 Bex1 Human Unknown 35.39 0.324 
A2 WRL68 Bex1 Bex1 Human Unknown 34.91 0.324 
A3 WRL68 Bex1 Bex1 Human Unknown 34.77 0.324 
A4 SK-HEP Bex1 Bex1 Human Unknown 33.03 0.054 
A5 SK-HEP Bex1 Bex1 Human Unknown 33.12 0.054 
A6 SK-HEP Bex1 Bex1 Human Unknown 33.12 0.054 
A7 HEPG2 Bex1 Bex1 Human Unknown 20.76 0.060 
A8 HEPG2 Bex1 Bex1 Human Unknown 20.79 0.060 
A9 HEPG2 Bex1 Bex1 Human Unknown 20.88 0.060 
A10 Chang Bex1 Bex1 Human Unknown 35.87 0.363 
A11 Chang Bex1 Bex1 Human Unknown 35.36 0.363 
A12 Chang Bex1 Bex1 Human Unknown 35.16 0.363 
B1 HUH7 Bex1 Bex1 Human Unknown 23.20 0.045 
B2 HUH7 Bex1 Bex1 Human Unknown 23.27 0.045 
B3 HUH7 Bex1 Bex1 Human Unknown 23.18 0.045 
B4 HL28 Bex1 Bex1 Human Unknown 29.08 0.037 
B5 HL28 Bex1 Bex1 Human Unknown 29.08 0.037 
B6 HL28 Bex1 Bex1 Human Unknown 29.14 0.037 
B7 HL42 Bex1 Bex1 Human Unknown 26.13 0.025 
B8 HL42 Bex1 Bex1 Human Unknown 26.13 0.025 
B9 HL42 Bex1 Bex1 Human Unknown 26.09 0.025 
B10 HL50 Bex1 Bex1 Human Unknown 28.55 0.189 
B11 HL50 Bex1 Bex1 Human Unknown 28.24 0.189 
B12 HL50 Bex1 Bex1 Human Unknown 28.21 0.189 
C1 RT WRL68 Bex1 Bex1 Human Unknown Undetermined 
C2 RT WRL68 Bex1 Bex1 Human Unknown Undetermined 
C3 RT WRL68 Bex1 Bex1 Human Unknown Undetermined 
C4 RT HL50 Bex1 Bex1 Human Unknown Undetermined 
C5 RT HL50 Bex1 Bex1 Human Unknown Undetermined 
C6 RT HL50 Bex1 Bex1 Human Unknown Undetermined 
  
Baseline: 3-15 
Threshold: 0,2 
Table 4 
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Plate Type: Absolute Quantification 
 
User: ICMM8011 
 
Document Information 
Operator: ICMM8011 
Run Date: Friday  April 08  2011 12:48:13 
Last Modified: Friday  April 08  2011 14:10:21 
Instrument Type: Applied Biosystems 7300 Real-Time PCR System 
Comments: 
SDS v1.3.1 
Thermal Cycler Profile 
Stage Repetitions Temperature Time Ramp Rate 
Auto  
Increment 
1 1 95.0 °C 10:00 Auto 
2 40 95.0 °C 00:15 Auto 
60.0 °C 01:00 Auto 
Standard 7300 Mode 
Data Collection :  Stage 2 Step 1 
PCR Volume: 15 µL 
Well Sample Name Detector Task Ct StdDev Ct 
D1 WRL68 Bex2 Bex2 Human Unknown 27.42 0.126 
D2 WRL68 Bex2 Bex2 Human Unknown 27.35 0.126 
D3 WRL68 Bex2 Bex2 Human Unknown 27.18 0.126 
D4 SK-HEP Bex2 Bex2 Human Unknown 25.24 0.038 
D5 SK-HEP Bex2 Bex2 Human Unknown 25.19 0.038 
D6 SK-HEP Bex2 Bex2 Human Unknown 25.16 0.038 
D7 HEPG2 Bex2 Bex2 Human Unknown 27.45 0.025 
D8 HEPG2 Bex2 Bex2 Human Unknown 27.45 0.025 
D9 HEPG2 Bex2 Bex2 Human Unknown 27.49 0.025 
D10 Chang Bex2 Bex2 Human Unknown 29.38 0.179 
D11 Chang Bex2 Bex2 Human Unknown 29.22 0.179 
D12 Chang Bex2 Bex2 Human Unknown 29.58 0.179 
E1 HUH7 Bex2 Bex2 Human Unknown 25.43 0.034 
E2 HUH7 Bex2 Bex2 Human Unknown 25.43 0.034 
E3 HUH7 Bex2 Bex2 Human Unknown 25.37 0.034 
E4 HL28 Bex2 Bex2 Human Unknown 33.73 0.623 
E5 HL28 Bex2 Bex2 Human Unknown 32.57 0.623 
E6 HL28 Bex2 Bex2 Human Unknown 32.77 0.623 
E7 HL42 Bex2 Bex2 Human Unknown 27.72 0.150 
E8 HL42 Bex2 Bex2 Human Unknown 27.45 0.150 
E9 HL42 Bex2 Bex2 Human Unknown 27.48 0.150 
E10 HL50 Bex2 Bex2 Human Unknown 26.40 0.099 
E11 HL50 Bex2 Bex2 Human Unknown 26.55 0.099 
E12 HL50 Bex2 Bex2 Human Unknown 26.37 0.099 
F1 RT WRL68 Bex2 Bex2 Human Unknown Undetermined 
F2 RT WRL68 Bex2 Bex2 Human Unknown Undetermined 
F3 RT WRL68 Bex2 Bex2 Human Unknown Undetermined 
F4 RT HL50 Bex2 Bex2 Human Unknown Undetermined 
F5 RT HL50 Bex2 Bex2 Human Unknown Undetermined 
F6 RT HL50 Bex2 Bex2 Human Unknown Undetermined 
Baseline: 3-15 
Threshold: 0,1 
Table 5 
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3.4 Results of Real Time PCR Dilution Curves   
 
Document Name: Bex1Bex2 dilution curves HL42 Andrea12042011  
 
Plate Type: Absolute Quantification 
User: ICMM8011 
Document Information 
Operator: ICMM8011 
Run Date: Tuesday  April 12  2011 14:17:56 
Last Modified: Tuesday  April 12  2011 15:40:35 
Instrument Type: Applied Biosystems 7300 Real-Time PCR System 
Comments: 
SDS v1.3.1 
Thermal Cycler Profile 
Stage Repetitions Temperature Time Ramp Rate 
Auto 
Increment 
1 1 95.0 °C 10:00 Auto 
2 40 95.0 °C 00:15 Auto 
60.0 °C 01:00 Auto 
Standard 7300 Mode 
Data Collection :  Stage 2 Step 1 
PCR Volume: 15 µL 
Well Sample Name Detector Task Ct StdDev Ct 
A1 8 Bex1 Bex1 Human Unknown 21.24 0.187 
A2 8 Bex1 Bex1 Human Unknown 21.61 0.187 
A3 8 Bex1 Bex1 Human Unknown 21.41 0.187 
A4 4 Bex1 Bex1 Human Unknown 22.52 0.058 
A5 4 Bex1 Bex1 Human Unknown 22.63 0.058 
A6 4 Bex1 Bex1 Human Unknown 22.55 0.058 
A7 2 Bex1 Bex1 Human Unknown 23.68 0.068 
A8 2 Bex1 Bex1 Human Unknown 23.54 0.068 
A9 2 Bex1 Bex1 Human Unknown 23.59 0.068 
A10 1 Bex1 Bex1 Human Unknown 24.56 0.137 
A11 1 Bex1 Bex1 Human Unknown 24.53 0.137 
A12 1 Bex1 Bex1 Human Unknown 24.78 0.137 
B1 0.5 Bex1 Bex1 Human Unknown 25.97 0.326 
B2 0.5 Bex1 Bex1 Human Unknown 25.38 0.326 
B3 0.5 Bex1 Bex1 Human Unknown 25.44 0.326 
B4 0.25 Bex1 Bex1 Human Unknown 26.64 0.143 
B5 0.25 Bex1 Bex1 Human Unknown 26.91 0.143 
B6 0.25 Bex1 Bex1 Human Unknown 26.86 0.143 
B7 0.125 Bex1 Bex1 Human Unknown 27.38 0.232 
B8 0.125 Bex1 Bex1 Human Unknown 27.84 0.232 
B9 0.125 Bex1 Bex1 Human Unknown 27.54 0.232 
B10 0.0625 Bex1 Bex1 Human Unknown 27.81 0.472 
B11 0.0625 Bex1 Bex1 Human Unknown 28.42 0.472 
B12 0.0625 Bex1 Bex1 Human Unknown 27.49 0.472 
C1 0.03125 Bex1 Bex1 Human Unknown 30.74 0.700 
C2 0.03125 Bex1 Bex1 Human Unknown 29.68 0.700 
C3 0.03125 Bex1 Bex1 Human Unknown 29.42 0.700 
C4 0.0156 Bex1 Bex1 Human Unknown 31.34 0.014 
C5 0.0156 Bex1 Bex1 Human Unknown 31.36 0.014 
C6 0.0156 Bex1 Bex1 Human Unknown 31.33 0.014 
C7 0.0078 Bex1 Bex1 Human Unknown 32.93 0.048 
C8 0.0078 Bex1 Bex1 Human Unknown 32.97 0.048 
C9 0.0078 Bex1 Bex1 Human Unknown 32.87 0.048 
Baseline: 3-15 
Threshold: 0,05 
Table 6 
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C10 0.0039 Bex1 Bex1 Human Unknown 32.42 1.118 
C11 0.0039 Bex1 Bex1 Human Unknown 33.08 1.118 
C12 0.0039 Bex1 Bex1 Human Unknown 34.60 1.118 
D1 0.00195 Bex1 Bex1 Human Unknown 34.76 0.799 
D2 0.00195 Bex1 Bex1 Human Unknown 33.98 0.799 
D3 0.00195 Bex1 Bex1 Human Unknown 33.17 0.799 
D4 0.00098 Bex1 Bex1 Human Unknown 35.21 
D5 0.00098 Bex1 Bex1 Human Unknown Undetermined 
D6 0.00098 Bex1 Bex1 Human Unknown Undetermined 
D7 0.0005 Bex1 Bex1 Human Unknown Undetermined 
D8 0.0005 Bex1 Bex1 Human Unknown Undetermined 
D9 0.0005 Bex1 Bex1 Human Unknown Undetermined 
D10 0.00024 Bex1 Bex1 Human Unknown 36.47 0.413 
D11 0.00024 Bex1 Bex1 Human Unknown Undetermined 
 
 
 
 
 
Dilution Curve Bex1: 
 
 
 
 
 
 
 
  
y = -3,337x + 24,55
R² = 0,989
0
5
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20
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35
40
-4 -3 -2 -1 0 1 2
Ct
Log µl cDNA
Log ul cDNA vs. Ct
Log ul cDNA 
vs. Ct
0,05
Chart 5 
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Document Name: Bex1Bex2 dilution curves HL42 Andrea12042011  
 
Plate Type: Absolute Quantification 
User: ICMM8011 
Document Information 
Operator: ICMM8011 
Run Date: Tuesday  April 12  2011 14:17:56 
Last Modified: Tuesday  April 12  2011 15:40:35 
Instrument Type: Applied Biosystems 7300 Real-Time PCR System 
Comments: 
SDS v1.3.1 
Thermal Cycler Profile 
Stage Repetitions Temperature Time Ramp Rate 
Auto  
Increment 
1 1 95.0 °C 10:00 Auto 
2 40 95.0 °C 00:15 Auto 
60.0 °C 01:00 Auto 
Standard 7300 Mode 
Data Collection :  Stage 2 Step 1 
PCR Volume: 15 µL 
Well Sample Name Detector Task Ct 
StdDev  
Ct 
E1 8 Bex2 Bex2 Human Unknown 27.65 0.356 
E2 8 Bex2 Bex2 Human Unknown 27.26 0.356 
E3 8 Bex2 Bex2 Human Unknown 26.94 0.356 
E4 4 Bex2  Bex2 Human Unknown 27.02 0.171 
E5 4 Bex2  Bex2 Human Unknown 26.87 0.171 
E6 4 Bex2  Bex2 Human Unknown 26.67 0.171 
E7 2 Bex2 Bex2 Human Unknown 28.22 0.109 
E8 2 Bex2 Bex2 Human Unknown 28.02 0.109 
E9 2 Bex2 Bex2 Human Unknown 28.06 0.109 
E10 1 Bex2 Bex2 Human Unknown 28.96 0.040 
E11 1 Bex2 Bex2 Human Unknown 28.96 0.040 
E12 1 Bex2 Bex2 Human Unknown 29.03 0.040 
F1 0.5 Bex2 Bex2 Human Unknown 30.23 0.136 
F2 0.5 Bex2 Bex2 Human Unknown 30.45 0.136 
F3 0.5 Bex2 Bex2 Human Unknown 30.21 0.136 
F4 0.25 Bex2 Bex2 Human Unknown 31.57 0.143 
F5 0.25 Bex2 Bex2 Human Unknown 31.29 0.143 
F6 0.25 Bex2 Bex2 Human Unknown 31.38 0.143 
F7 0.125 Bex2 Bex2 Human Unknown 32.28 0.144 
F8 0.125 Bex2 Bex2 Human Unknown 32.01 0.144 
F9 0.125 Bex2 Bex2 Human Unknown 32.24 0.144 
F10 0.0625 Bex2 Bex2 Human Unknown 33.32 0.228 
F11 0.0625 Bex2 Bex2 Human Unknown 33.43 0.228 
F12 0.0625 Bex2 Bex2 Human Unknown 32.99 0.228 
G1 0.03125 Bex2 Bex2 Human Unknown 34.20 0.033 
G2 0.03125 Bex2 Bex2 Human Unknown 34.26 0.033 
G3 0.03125 Bex2 Bex2 Human Unknown 34.21 0.033 
G4 0.01563 Bex2 Bex2 Human Unknown 35.19 0.380 
G5 0.01563 Bex2 Bex2 Human Unknown 35.32 0.380 
G6 0.01563 Bex2 Bex2 Human Unknown 34.60 0.380 
G7 0.0078 Bex2 Bex2 Human Unknown 36.11 0.635 
G8 0.0078 Bex2 Bex2 Human Unknown 36.13 0.635 
G9 0.0078 Bex2 Bex2 Human Unknown 37.22 0.635 
Baseline: 3-15 
Threshold: 0,1 
Table 7
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G10 0.00391 Bex2 Bex2 Human Unknown 38.18 0.834 
G11 0.00391 Bex2 Bex2 Human Unknown Undetermined 
G12 0.00391 Bex2 Bex2 Human Unknown 39.36 0.834 
H1 0.00195 Bex2 Bex2 Human Unknown Undetermined 
H2 0.00195 Bex2 Bex2 Human Unknown 38.16 1.035 
H3 0.00195 Bex2 Bex2 Human Unknown 39.62 1.035 
H4 0.00098 Bex2 Bex2 Human Unknown 37.75 0.911 
H5 0.00098 Bex2 Bex2 Human Unknown Undetermined 
H6 0.00098 Bex2 Bex2 Human Unknown 39.04 0.911 
H7 0.0005 Bex2 Bex2 Human Unknown Undetermined 
H8 0.0005 Bex2 Bex2 Human Unknown 38.76 
H9 0.0005 Bex2 Bex2 Human Unknown Undetermined 
H10 0.00024 Bex2 Bex2 Human Unknown Undetermined 
H11 0.00024 Bex2 Bex2 Human Unknown Undetermined 
H12 0.00024 Bex2 Bex2 Human Unknown Undetermined 
 
 
 
 
 
Dilution Curve Bex2: 
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3.5 Real Time PCR Results  
 
 
Document Name: Bex1Bex2  Human livers  13-04-2011  
 
Plate Type: Absolute Quantification 
User: ICMM8011 
Document Information 
Operator: ICMM8011 
Run Date: Wednesday  April 13 
 2011 
14:06:55 
Last Modified: Wednesday  April 13 
 2011 
15:29:16 
Instrument Type: Applied Biosystems 7300 Real-Time PCR System 
Comments: 
SDS v1.3.1 
Thermal Cycler Profile 
Stage Repetitions Temperature Time Ramp Rate 
Auto  
Increment 
1 1 95.0 ｰC 10:00 Auto 
2 40 95.0 ｰC 00:15 Auto 
60.0 ｰC 01:00 Auto 
Standard 7300 Mode 
Data Collection :  Stage 2 Step 1 
PCR Volume: 15 µL 
Well Sample Name Detector Task Ct StdDev Ct 
A1 HL26 Bex1 Bex1 Human Unknown 27.59 0.030 
A2 HL26 Bex1 Bex1 Human Unknown 27.62 0.030 
A3 HL26 Bex1 Bex1 Human Unknown 27.56 0.030 
A4 HL27 Bex1 Bex1 Human Unknown 25.52 0.140 
A5 HL27 Bex1 Bex1 Human Unknown 25.25 0.140 
A6 HL27 Bex1 Bex1 Human Unknown 25.33 0.140 
A7 HL28 Bex1 Bex1 Human Unknown 28.28 0.144 
A8 HL28 Bex1 Bex1 Human Unknown 28.05 0.144 
A9 HL28 Bex1 Bex1 Human Unknown 28.32 0.144 
A10 HL32 Bex1 Bex1 Human Unknown 26.04 0.257 
A11 HL32 Bex1 Bex1 Human Unknown 26.33 0.257 
A12 HL32 Bex1 Bex1 Human Unknown 26.55 0.257 
B1 HL33 Bex1 Bex1 Human Unknown 28.28 0.126 
B2 HL33 Bex1 Bex1 Human Unknown 28.12 0.126 
B3 HL33 Bex1 Bex1 Human Unknown 28.03 0.126 
B4 HL36 Bex1 Bex1 Human Unknown 27.51 0.273 
B5 HL36 Bex1 Bex1 Human Unknown 27.22 0.273 
B6 HL36 Bex1 Bex1 Human Unknown 26.96 0.273 
B7 HL38 Bex1 Bex1 Human Unknown 27.45 0.156 
B8 HL38 Bex1 Bex1 Human Unknown 27.76 0.156 
B9 HL38 Bex1 Bex1 Human Unknown 27.66 0.156 
B10 HL42 Bex1 Bex1 Human Unknown 25.10 0.253 
B11 HL42 Bex1 Bex1 Human Unknown 24.66 0.253 
B12 HL42 Bex1 Bex1 Human Unknown 24.66 0.253 
C1 HL43 Bex1 Bex1 Human Unknown 28.33 0.671 
C2 HL43 Bex1 Bex1 Human Unknown 27.28 0.671 
C3 HL43 Bex1 Bex1 Human Unknown 27.07 0.671 
C4 HL44 Bex1 Bex1 Human Unknown 28.05 0.296 
Baseline: 3-15 
Threshold: 0,05 
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C5 HL44 Bex1 Bex1 Human Unknown 27.85 0.296 
C6 HL44 Bex1 Bex1 Human Unknown 27.47 0.296 
C7 HL47 Bex1 Bex1 Human Unknown 29.03 0.133 
C8 HL47 Bex1 Bex1 Human Unknown 29.25 0.133 
C9 HL47 Bex1 Bex1 Human Unknown 29.02 0.133 
C10 HL49 Bex1 Bex1 Human Unknown 29.59 0.359 
C11 HL49 Bex1 Bex1 Human Unknown 28.88 0.359 
C12 HL49 Bex1 Bex1 Human Unknown 29.19 0.359 
D1 HL52 Bex1 Bex1 Human Unknown 26.87 0.053 
D2 HL52 Bex1 Bex1 Human Unknown 26.79 0.053 
D3 HL52 Bex1 Bex1 Human Unknown 26.76 0.053 
D4 HL54 Bex1 Bex1 Human Unknown 25.37 0.091 
D5 HL54 Bex1 Bex1 Human Unknown 25.19 0.091 
D6 HL54 Bex1 Bex1 Human Unknown 25.25 0.091 
D7 HL62 Bex1 Bex1 Human Unknown 28.18 0.054 
D8 HL62 Bex1 Bex1 Human Unknown 28.07 0.054 
D9 HL62 Bex1 Bex1 Human Unknown 28.13 0.054 
D10 Minus RT Bex1 Bex1 Human Unknown Undetermined 
D11 Minus RT Bex1 Bex1 Human Unknown Undetermined 
D12 Minus RT Bex1 Bex1 Human Unknown Undetermined 
 
 
 
Document Name: Bex1Bex2  Human livers  13-04-2011  
 
Plate Type: Absolute Quantification 
User: ICMM8011 
Document Information 
Operator: ICMM8011 
Run Date: Wednesday  April 13 
 2011 
14:06:55 
Last Modified: Wednesday  April 13 
 2011 
15:29:16 
Instrument Type: Applied Biosystems 7300 Real-Time PCR System 
Comments: 
SDS v1.3.1 
Thermal Cycler Profile 
Stage Repetitions Temperature Time Ramp Rate 
Auto  
Increment 
1 1 95.0 ｰC 10:00 Auto 
2 40 95.0 ｰC 00:15 Auto 
60.0 ｰC 01:00 Auto 
Standard 7300 Mode 
Data Collection :  Stage 2 Step 1 
PCR Volume: 15 µL 
Well Sample Name Detector Task Ct StdDev Ct 
E1 HL26 Bex2 Bex2 Human Unknown 31.25 0.210 
E2 HL26 Bex2 Bex2 Human Unknown 30.83 0.210 
E3 HL26 Bex2 Bex2 Human Unknown 31.07 0.210 
E4 HL27 Bex2 Bex2 Human Unknown 30.11 0.082 
E5 HL27 Bex2 Bex2 Human Unknown 30.19 0.082 
E6 HL27 Bex2 Bex2 Human Unknown 30.02 0.082 
Baseline: 3-15 
Threshold: 0,1 
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E7 HL28 Bex2 Bex2 Human Unknown 35.08 0.546 
E8 HL28 Bex2 Bex2 Human Unknown 34.18 0.546 
E9 HL28 Bex2 Bex2 Human Unknown 34.09 0.546 
E10 HL32 Bex2 Bex2 Human Unknown 30.19 0.076 
E11 HL32 Bex2 Bex2 Human Unknown 30.34 0.076 
E12 HL32 Bex2 Bex2 Human Unknown 30.23 0.076 
F1 HL33 Bex2 Bex2 Human Unknown 32.08 0.268 
F2 HL33 Bex2 Bex2 Human Unknown 31.55 0.268 
F3 HL33 Bex2 Bex2 Human Unknown 31.72 0.268 
F4 HL36 Bex2 Bex2 Human Unknown 30.20 0.079 
F5 HL36 Bex2 Bex2 Human Unknown 30.36 0.079 
F6 HL36 Bex2 Bex2 Human Unknown 30.27 0.079 
F7 HL38 Bex2 Bex2 Human Unknown 30.93 0.288 
F8 HL38 Bex2 Bex2 Human Unknown 30.36 0.288 
F9 HL38 Bex2 Bex2 Human Unknown 30.53 0.288 
F10 HL42 Bex2 Bex2 Human Unknown 29.52 0.098 
F11 HL42 Bex2 Bex2 Human Unknown 29.33 0.098 
F12 HL42 Bex2 Bex2 Human Unknown 29.38 0.098 
G1 HL43 Bex2 Bex2 Human Unknown 30.08 0.211 
G2 HL43 Bex2 Bex2 Human Unknown 29.67 0.211 
G3 HL43 Bex2 Bex2 Human Unknown 29.77 0.211 
G4 HL44 Bex2 Bex2 Human Unknown 31.43 0.110 
G5 HL44 Bex2 Bex2 Human Unknown 31.26 0.110 
G6 HL44 Bex2 Bex2 Human Unknown 31.22 0.110 
G7 HL47 Bex2 Bex2 Human Unknown 31.62 0.167 
G8 HL47 Bex2 Bex2 Human Unknown 31.38 0.167 
G9 HL47 Bex2 Bex2 Human Unknown 31.30 0.167 
G10 HL49 Bex2 Bex2 Human Unknown 31.80 0.359 
G11 HL49 Bex2 Bex2 Human Unknown 31.16 0.359 
G12 HL49 Bex2 Bex2 Human Unknown 31.20 0.359 
H1 HL52 Bex2 Bex2 Human Unknown 30.72 0.395 
H2 HL52 Bex2 Bex2 Human Unknown 30.17 0.395 
H3 HL52 Bex2 Bex2 Human Unknown 29.96 0.395 
H4 HL54 Bex2 Bex2 Human Unknown 29 1 
H5 HL54 Bex2 Bex2 Human Unknown 30,03 1 
H6 HL54 Bex2 Bex2 Human Unknown 
H7 HL62 Bex2 Bex2 Human Unknown 30.95 0.176 
H8 HL62 Bex2 Bex2 Human Unknown 30.60 0.176 
H9 HL62 Bex2 Bex2 Human Unknown 30.72 0.176 
H10 Minus RT Bex2 Bex2 Human Unknown Undetermined 
H11 Minus RT Bex2 Bex2 Human Unknown Undetermined 
H12 Minus RT Bex2 Bex2 Human Unknown Undetermined 
 
 
 
 
 
 
 
 
 
 
- 80 - 
 
3.6 Real Time PCR Calculations 
 
The Comparative C
T 
Method (∆∆ C
T 
Method)  
The Comparative CT Method, also referred to as the ∆∆CT Method ,it uses 
arithmetic formulas to achieve the result for relative quantitation.  
Arithmetic Formula:  
The amount of target, normalized to an endogenous reference and relative to a 
calibrator, is given by:  
 
 
2 
–∆∆C
T  
 
1. Calculate the mean and standard deviation values of the replicate 
sample results.  
Mean CT values and standard deviations can be calculated in Microsoft® Excel 
software 
2. Calculate the ∆CT value.  
The ∆CT value is calculated by:  
 
∆CT = CT target – CT reference  
 
3.  Calculate the standard deviation of the ∆CT value.  
The standard deviation of the ∆CT is calculated from the standard deviations of the 
target and reference values using the formula:  
 
s = (s12 + s22)1/2   
where X1/2 is the square root of X and s= standard deviation 
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4. Calculate the ∆∆CT value.  
The ∆∆CT is calculated by:  
 
∆∆CT = ∆CT test sample – ∆CT calibrator sample 
 
5. Calculate the standard deviation of the ∆∆CT value. 
The calculation of ∆∆CT involves subtraction of the ∆CT calibrator value. This is 
subtraction of an arbitrary constant, so the standard deviation of the ∆∆CT value is 
the same as the standard deviation of the ∆CT value. 
 
6. Incorporating the standard deviation of the ∆∆CT values into the fold-
difference.  
Fold-differences calculated using the ∆∆CT method are usually expressed as a 
range, which is a result of incorporating the standard deviation of the ∆∆CT value 
into the fold-difference calculation.  
The range for targetN, relative to a calibrator sample, is calculated by: 2–∆∆Ct with 
∆∆CT + s and ∆∆CT – s, where s is the standard deviation of the ∆∆CT value. 
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Well 
Sample  
Name 
Detector Ct 
 StdDev  
Ct (S1) 
Bex1 mean 
Average for controls  
(HL28, HL33,HL47,HL49) 
A1 HL26 Bex1 Bex1 27,59 0,03 
  A2 HL26 Bex1 Bex1 27,62 0,03 
  A3 HL26 Bex1 Bex1 27,56 0,03 27,59 
 A4 HL27 Bex1 Bex1 25,52 0,14 
  A5 HL27 Bex1 Bex1 25,25 0,14 
  A6 HL27 Bex1 Bex1 25,33 0,14 25,36666667 
 A7 HL28 Bex1 Bex1 28,28 0,144 
  A8 HL28 Bex1 Bex1 28,05 0,144 
  A9 HL28 Bex1 Bex1 28,32 0,144 28,21666667 28,67 
A10 HL32 Bex1 Bex1 26,04 0,257 
  A11 HL32 Bex1 Bex1 26,33 0,257 
  A12 HL32 Bex1 Bex1 26,55 0,257 26,30666667 
 B1 HL33 Bex1 Bex1 28,28 0,126 
  B2 HL33 Bex1 Bex1 28,12 0,126 
  B3 HL33 Bex1 Bex1 28,03 0,126 28,14333333 
 B4 HL36 Bex1 Bex1 27,51 0,273 
  B5 HL36 Bex1 Bex1 27,22 0,273 
  B6 HL36 Bex1 Bex1 26,96 0,273 27,23 
 B7 HL38 Bex1 Bex1 27,45 0,156 
  B8 HL38 Bex1 Bex1 27,76 0,156 
  B9 HL38 Bex1 Bex1 27,66 0,156 27,62333333 
 B10 HL42 Bex1 Bex1 25,1 0,253 
  B11 HL42 Bex1 Bex1 24,66 0,253 
  B12 HL42 Bex1 Bex1 24,66 0,253 24,80666667 
 C1 HL43 Bex1 Bex1 28,33 0,671 
  C2 HL43 Bex1 Bex1 27,28 0,671 
  C3 HL43 Bex1 Bex1 27,07 0,671 27,56 
 C4 HL44 Bex1 Bex1 28,05 0,296 
  C5 HL44 Bex1 Bex1 27,85 0,296 
  C6 HL44 Bex1 Bex1 27,47 0,296 27,79 
 C7 HL47 Bex1 Bex1 29,03 0,133 
  C8 HL47 Bex1 Bex1 29,25 0,133 
  C9 HL47 Bex1 Bex1 29,02 0,133 29,1 
 C10 HL49 Bex1 Bex1 29,59 0,359 
  C11 HL49 Bex1 Bex1 28,88 0,359 
  C12 HL49 Bex1 Bex1 29,19 0,359 29,22 
 D1 HL52 Bex1 Bex1 26,87 0,053 
  D2 HL52 Bex1 Bex1 26,79 0,053 
  D3 HL52 Bex1 Bex1 26,76 0,053 26,80666667 
 D4 HL54 Bex1 Bex1 25,37 0,091 
  D5 HL54 Bex1 Bex1 25,19 0,091 
  
       
Fold Change Bex1 
Table 10 
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ΔCT = CT test sample - Ct 
calibrator sample 
(HL28,HL33,HL47,HL49) 
±S  ΔCT+S ΔCT-S 
Fold change (ΔCT+S) =  
2
-ΔCT+S
 
-1,08 0,030 -1,05 -1,11 2,070529848 
-3,303333333 0,14 -3,163333333 -3,443333333 8,958972832 
-0,453333333 0,144 -0,309333333 -0,597 1,239134966 
-2,363333333 0,257 -2,106333333 -2,620333333 4,305955271 
-0,526666667 0,126 -0,401 -0,653 1,320 
-1,44 0,273 -1,167 -1,713 2,245442844 
-1,046666667 0,156 -0,891 -1,203 1,854032671 
-3,863333333 0,253 -3,610333333 -4,116333333 12,21289512 
-1,11 0,671 -0,439 -1,781 1,355664327 
-0,88 0,296 -0,584 -1,176 1,498999602 
0,43 0,133 0,563 0,297 0,67689314 
0,55 0,359 0,909 0,191 0,532554102 
-1,863333333 0,053 -1,810333333 -1,916333333 3,507233135 
-3,4 0,091 -3,309 -3,491 9,910789582 
-0,543333333 0,054 -0,489333333 -0,597333333 1,403796034 
 
 
Well 
Sample  
Name 
Detector Ct 
 StdDev Ct 
(S1) 
Bex2 mean 
Average for controls  
(HL28, HL33,HL47,HL49) 
A1 HL26 Bex2 Bex2 31,25 0,21 
  A2 HL26 Bex2 Bex2 30,83 0,21 
  A3 HL26 Bex2 Bex2 31,07 0,21 31,05 
 A4 HL27 Bex2 Bex2 30,11 0,082 
  A5 HL27 Bex2 Bex2 30,19 0,082 
  A6 HL27 Bex2 Bex2 30,02 0,082 30,10666667 
 A7 HL28 Bex2 Bex2 35,08 0,546 
  A8 HL28 Bex2 Bex2 34,18 0,546 
  A9 HL28 Bex2 Bex2 34,09 0,546 34,135 32,18458333 
A10 HL32 Bex2 Bex2 30,19 0,076 
  A11 HL32 Bex2 Bex2 30,34 0,076 
  A12 HL32 Bex2 Bex2 30,23 0,076 30,25333333 
 B1 HL33 Bex2 Bex2 32,08 0,268 
  B2 HL33 Bex2 Bex2 31,55 0,268 
  B3 HL33 Bex2 Bex2 31,72 0,268 31,78333333 
 B4 HL36 Bex2 Bex2 30,2 0,079 
  B5 HL36 Bex2 Bex2 30,36 0,079 
  B6 HL36 Bex2 Bex2 30,27 0,079 30,27666667 
 B7 HL38 Bex2 Bex2 30,93 0,288 
  
D6 HL54 Bex1 Bex1 25,25 0,091 25,27 
 D7 HL62 Bex1 Bex1 28,18 0,054 
  D8 HL62 Bex1 Bex1 28,07 0,054 
  D9 HL62 Bex1 Bex1 28,13 0,054 28,12666667 
 
Fold Change Bex2 
Table 11 
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B8 HL38 Bex2 Bex2 30,36 0,288 
  B9 HL38 Bex2 Bex2 30,53 0,288 30,73 
 B10 HL42 Bex2 Bex2 29,52 0,098 
  B11 HL42 Bex2 Bex2 29,33 0,098 
  B12 HL42 Bex2 Bex2 29,38 0,098 29,41 
 C1 HL43 Bex2 Bex2 30,08 0,211 
  C2 HL43 Bex2 Bex2 29,67 0,211 
  C3 HL43 Bex2 Bex2 29,77 0,211 29,84 
 C4 HL44 Bex2 Bex2 31,43 0,11 
  C5 HL44 Bex2 Bex2 31,26 0,11 
  C6 HL44 Bex2 Bex2 31,22 0,11 31,30333333 
 C7 HL47 Bex2 Bex2 31,62 0,167 
  C8 HL47 Bex2 Bex2 31,38 0,167 
  C9 HL47 Bex2 Bex2 31,3 0,167 31,43333333 
 C10 HL49 Bex2 Bex2 31,8 0,359 
  C11 HL49 Bex2 Bex2 31,16 0,359 
  C12 HL49 Bex2 Bex2 31,2 0,359 31,38666667 
 D1 HL52 Bex2 Bex2 30,72 0,395 
  D2 HL52 Bex2 Bex2 30,17 0,395 
  D3 HL52 Bex2 Bex2 29,96 0,395 30,28333333 
 D4 HL54 Bex2 Bex2 29 1 
  D6 HL54 Bex2 Bex2 
 
1 29 
 D7 HL62 Bex2 Bex2 30,95 0,176 
  D8 HL62 Bex2 Bex2 30,6 0,176 
  D9 HL62 Bex2 Bex2 30,72 0,176 30,75666667 
 
 
ΔCT = CT test sample - 
Ct calibrator sample 
(HL28,HL33,HL47,HL49) 
±S  ΔCT+S ΔCT-S 
Fold change 
(ΔCT+S) =  
2
-ΔCT+S
 
Fold change 
(ΔCT+S) =  
2
-ΔCT-S
 
-1,134583333 0,210 -0,925 -1,134583333 1,898 2,195551436 
-2,077916667 0,082 -1,995916667 -2,159916667 3,988694603 4,468890412 
1,950416667 0,546 2,496416667 1,404416667 0,177216315 0,377770862 
-1,93125 0,076 -1,85525 -2,00725 3,618144433 4,020151861 
-0,40125 0,268 -0,133 -0,669 1,097 1,590 
-1,907916667 0,079 -1,828916667 -1,986916667 3,552701965 3,963889283 
-1,454583333 0,288 -1,166583333 -1,742583333 2,244794428 3,346338371 
-2,774583333 0,098 -2,676583333 -2,872583333 6,39339989 7,323754003 
-2,344583333 0,211 -2,133583333 -2,555583333 4,388060246 5,879051164 
-0,88125 0,11 -0,77125 -0,99125 1,706747927 1,987906635 
-0,75125 0,167 -0,58425 -0,91825 1,499259381 1,889821535 
-0,797916667 0,359 -0,438916667 -1,156916667 1,355586023 2,229803635 
-1,90125 0,395 -1,50625 -2,29625 2,840706931 4,911793811 
-3,184583333 1 -2,184583333 -4,184583333 4,54595478 18,18381912 
-1,427916667 0,176 -1,251916667 -1,603916667 2,38157613 3,039674129 
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Normalization 
 
 
 
 
donor media Bex1 dev st media Bex1 donor media Bex2 dev st media Bex2 
28,82111111 0,590031386 31,53444444 0,216803376 
ΔCt (Bex1-Bex2) bex1 st dev bex2 st dev s1
2
 +s2
2
 
dev standard  
(bex1-bex2) 
-2,713333333 donor 0,590031386 donor             0,217 donor 0,39514074 0,628602212 
-3,46 0,03 0,21 0,045 0,212132034 
-4,74 0,14 0,082 0,026324 0,162246726 
-5,918333333 0,144 0,546 0,318852 0,564669815 
-3,946666667 0,257 0,076 0,071825 0,268001866 
-3,64 0,126 0,268 0,0877 0,296141858 
-3,046666667 0,273 0,079 0,08077 0,284200633 
-3,106666667 0,156 0,288 0,10728 0,327536258 
-4,603333333 0,253 0,098 0,073613 0,271317158 
-2,28 0,671 0,211 0,494762 0,703393204 
-3,513333333 0,296 0,11 0,099716 0,315778403 
-2,333333333 0,133 0,167 0,045578 0,213490047 
-2,166666667 0,359 0,359 0,257762 0,507702669 
-3,476666667 0,053 0,395 0,158834 0,398539835 
-3,73 0,091 1 1,008281 1,004131963 
-2,63 0,054 0,176 0,033892 0,1840978 
ΔΔCt(ΔCt tr-ΔCt donor) change fold(2
-ΔΔCt
) chage fold-dev.stand change fold+dev.stand 
0 1 0,371397788 1,628602212 
-0,746666667 1,67791155 1,465779515 1,890043584 
-2,026666667 4,07462324 3,912376514 4,236869966 
-3,205 9,221490774 8,656820959 9,786160589 
-1,233333333 2,351095813 2,083093947 2,619097678 
-0,926666667 1,900878955 1,604737098 2,197020813 
-0,333333333 1,25992105 0,975720417 1,544121683 
-0,393333333 1,313424556 0,985888298 1,640960813 
-1,89 3,706352248 3,43503509 3,977669405 
0,433333333 0,740548776 0,037155572 1,443941981 
-0,8 1,741101127 1,425322723 2,05687953 
0,38 0,768437591 0,554947544 0,981927637 
0,546666667 0,684600064 0,176897396 1,192302733 
-0,763333333 1,697407943 1,298868108 2,095947778 
-1,016666667 2,023238881 1,019106917 3,027370844 
0,083333333 0,943874313 0,759776513 1,127972113 
Table 12 
- 86 - 
 
3.7 Real Time PCR Charts (GraphPad Prism) 
  
Ct values Bex1
Do
no
r L
ive
r H
L4
7
Do
no
r L
ive
r H
L4
9
He
alt
hy
 
Liv
er
 
(res
ec
tio
n) H
L2
8
He
alt
hy
 
Liv
er
 
HL
33
Pr
.
 
Bil
.
 
Cir
rho
sis
 
(PB
C) H
L2
6
Pr
.
 
Bil
.
 
Cir
rho
sis
 
(PB
C) H
L3
8
Pr
.
 
Bil
.
 
Sc
ler
os
is 
(PB
S)  
HL
54
Sc
ler
os
ing
 
Ch
ola
ng
itis
 
HL
62
Pr
.
Sc
l. C
ho
lan
git
is 
(PS
C) H
L5
2
Ad
ult
 
Du
cto
pe
ni-
Cir
rho
sis
? H
L3
2
Alc
.
 
Sc
ler
os
is-
Cir
rho
sis
? H
L3
6
Alc
oh
oli
c 
Liv
er
 
Dis
ea
se
 
HL
27
Alc
oh
oli
c 
Liv
er
 
Dis
ea
se
 
HL
44
To
xic
 
Liv
er
 
Dis
ea
se
 
HL
43
 
Pa
ra
ce
tam
ol 
Int
ox
ica
tio
n 
HL
42
22
24
26
28
30
32
Ct
Chart 7 
- 87 - 
 
 
  
Ct values Bex2
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Fold change Bex1
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Fold change Bex2
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Regression Analysis Correlation between
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3.8 Antibody Optimization Results 
 
Results Dilution 1:3000: 
 
 
Heh 9891/05 Good 
Heh 1293/05 Nothing 
Heh 5841/05 Good 
Heh 5927/05 Nothing 
Heh 97-769 Nothing 
Heh 05-8427 Good 
Heh 96-4131 Nothing 
Heh 96-9136 Nothing 
Heh 96-7246 Nothing 
Heh 01-5050 Nothing 
Heh 00-1574 Nothing 
Heh 01-4389 No so good 
Heh 01-9799 Nothing 
Heh 01-8812 Nothing 
Heh 01-10385 Nothing 
Heh 01-7957 Nothing 
Heh 05-11093 Nothing 
Heh 05-9836 Nothing 
Heh 04-10412 Nothing 
Heh 04-12676 Good 
Heh 98-15474 Good 
Heh 98-6307 Nothing 
Heh 04-1873 Nothing 
Heh 00-3800 Good 
 
 
 
 
 
Donor 
PBC 
PSC 
 St.Hep. 
Toxic 
LDO 
Bex1 
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Results Dilution 1:1500: 
 
 
 
 
Heh 97-10915 Ok, much background Ok 
Heh 00-3800 No so good, much 
background 
Ok 
Heh 98-6307 No No 
Heh 04-1873 No No 
Heh 98-9178 Maybe, much 
background 
Ok 
Heh 98-15479 Ok, much background Ok 
Heh 96-8703 Ok, much background Ok 
Heh 99-4107 Ok, much background Ok 
Heh 05-2939 Ok, much background Ok 
Heh 04-3811 Ok, much background Ok 
Heh 05-34 Maybe, much 
background 
Ok 
Heh 05-1535 Ok, much background Ok 
Heh 03-5226 Ok, much background Ok 
Heh 03-9034 Ok, much background Ok 
Heh 03-3935 No No 
Heh 04-3327 Maybe Ok 
Heh 3318/04 Ok, but not very strong 
(mediocre) 
Ok, but not very strong 
Heh 13988/05 The best Works very well and 
strong 
Heh 03-4081 Works very well Works very well 
Heh 03-10562 Not very good (small 
tissue) 
Not very good (small 
tissue) 
Heh 03-3979 No No 
Heh 03-3372 Good (low background) Good 
Heh 02-10939 Not very good Not very good 
Heh 9842/05 Good (much 
background) 
Good 
Heh 1763/04 No No 
Heh 04-11788 Good (much 
background) 
Good 
Donor 
Bex1 CK19 
PBC 
Toxic 
St.Hep. 
LDO 
Table 14 
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Heh 00-1574 Ok Ok 
Heh 02-4674 Ok, nice Ok 
Heh 02-338 Ok, nice Ok 
Heh 04-3948 Ok, nice but much 
background 
Ok 
 
 
Dilution: 
For Bex1:  1:1500                 For CK19:  1:50 
                  1:15000                                 1:100 
                  1:50000 
                  1:100000 
                  1:150000 
                                                                 
 
Bex1  
1:1500 
Ok ,not much background 
Bex1  
1:15000 
Ok 
Bex1  
1:50000 
Ok, a bit light 
Bex1  
1:100000 
OK, but very light 
Bex1  
1:150000 
No 
CK19  
1:50 
Ok, perfect 
 
CK19  
1:100 
Ok 
 
 
 
 
 
 
 
 
PSC 
The following pictures shows the results reported in the previous table with four different 
magnifications. 
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3.9 Bex1 and CK19 Detection Results 
 
 
 
 
 
Heh 4901-05 No well  
Heh 2198-05 No well  
Heh 1353-05 Ok Ok 
Heh 6646-05 Ok Ok 
Heh 3971-05 Ok Ok 
Heh 11675-05 Ok Ok 
Heh 9219-05 Ok Ok 
Heh 14295-05 No well  
Heh 5918-05 Ok  
Heh 05-4436 No well Ok 
Heh 98-3916 No  
Heh 05-6097 Ok Ok 
Heh 05-8210 Ok Ok 
Heh 05-3836 No well  
Heh 05-2491 Ok Ok 
Heh 05-2990 No well  
Heh 00-9555 Ok, much background  
Heh 00-5451 Ok Ok 
Heh 01-10245 No  
Heh 05-11595 Ok  
Heh 05-7717 Ok Ok 
Heh 05-13288 Ok Ok 
Heh 04-3167 Ok Ok 
Heh 05-7718 No well Ok 
Heh 03-4558 No  
Heh 01-2678 No well Ok 
   
   
Bex1 
HCV 
HBV 
LDO 
CK19 
Table 16 
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Heh 97-769 Ok, much background Ok 
Heh 96-4131 No  
Heh 05-8427 Ok, much background  
Heh 03-8518 Ok Ok 
Heh 04-11276 Ok Ok 
Heh 99-17753 No well  
Heh 98-15474 Ok Ok 
HL 42 (1) Ok, much background  
HL 42 (2) Ok  
HL42 (15)  Ok 
Heh 04-10412 Ok, much background Ok 
Heh 04-8383 Ok Ok 
Heh 05-3487 Ok Ok 
Heh 01-5050 Ok Ok 
 
 
 
 
 
 
 
 
 
  
PBC 
Toxic 
St.Hep. 
PSC 
The following table shows a section for each liver disease with two different 
magnifications. 
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3.10 Bradford Assay Results 
Table 18 
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3.11 Western Blot Result 
 
 
 
 
 
Loaded 12µg of the samples on to the gel. 
 
M: SeeBlue plus pre-stained Standard Marker(LC5925). 
1 - 2 - 3: Water. 
4: Control (number 3 in Bradford assay, concentration 1,32mg/ml).  
5: Bex1(number 2 in Bradford assay, concentration 1,82mg/ml). 
 
 
 
 
 
 
Fig.24 
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4 DISCUSSION 
 
The first aim of this project was to understand if Bex1 and Bex2 are present in 
healthy and pathological liver tissues and to estimate their levels. Before beginning 
the Real-Time PCR, we used the Nanodrop technique to evaluate the 
concentration of RNA in our samples and than we determined the integrity or RNA 
by the Agilent 2100 Bioanalyzer. In Fig.21 we can see the electrophoresis of our 
samples and in Chart 1 the electropherograms, they show good peaks at 18S and 
28S and a RNA Integrity Number (RIN) around. These results prove a good quality 
of our RNAs  that are suitable for the Real Time PCR. 
We started with a pilot Real Time PCR on cell lines: WRL68, SK-HEP, HEPG2, 
Chang, HUH7 and liver tissues: HL28, HL42, HL50 to determine if there is an 
increase in the levels of Bex1 and Bex2. In Table 1 and Table 2 we can see a 
high level of Bex1 and Bex2 in hepatocellular carcinoma cell lines respect to 
normal cell and also in pathological liver tissues respect to normal tissues.   
After these observations we performed a Real Time PCR on HL42 to determine 
the Dilution Curves for Bex1 and Bex2. In Chart 5 and Chart 6 are shown the 
Dilution Curves: for Bex1 curve we have m = -3,337 and R2 = 0,989, for Bex2 
curve we have m = -3,317 and R2 = 0,997. So we have two good m values, very 
close to      -3,32, that is the value for 100% efficiency of reaction. We also have 
two good R2 values, the highest value being  0,999. The R2  is the correlation 
coefficient and reflects the linearity of standard curve,. 
After this, we performed a Real Time PCR on 15 different liver tissues: HL47, 
HL49, HL28, HL33 (healthy tissues); HL26, HL27, HL32, HL36, HL38, HL42, 
HL43, HL44, HL52, HL54, HL62 (pathological tissues). It is very important to 
notice that in our project we were unable to use a housekeeping gene as 
endogenous control, because all transcripts currently investigated including 
GAPDH, actin, TBP, s18 fluctuate during liver regeneration and liver disease. In 
Table 8 and Table 9 the Ct values of Bex1 and Bex2 are reported; in Table 10 
and Table 11 are shown all the calculations for the Fold Change of Bex1 and 
Bex2; in Chart 7, Chart 8, Chart 9 and Chart 10 there are the graphical 
representations of the results obtained by the GraphPad Prism program. An 
increase of Bex1 can be observed in all pathological liver tissue samples respect 
to normal tissues; the highest levels are seen for HL54 Primary Biliary Sclerosis 
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(PBS), HL27 Alcoholic Liver Disease, HL42 Paracetamol Intoxication. Instead the 
Ct values for Bex2 do not change significantly  in the different diseases and also in 
normal tissues; for this reason we decided to focalize our attention only on Bex1. 
We also tried to use Bex2 to normalize the results of Bex1, calculations and 
representation are visible in Table 12  and Chart 14. 
 
The second aim of the project was the immunodetection of Bex1 in healthy and 
pathological liver tissues. We began with a antibody optimization to determine the 
best antibody to detect Bex1 with the least possible background.  
We decided to use an immunodetection procedure based on Diaminobenzidine 
(DAB) as chromogen. We started using Bex1 antibody of Abcam (#ab69032) with 
a dilution of 1:100 on HL42 tissue, but the antibody did not result specific, likely 
because the dilution was very low. Then, we changed antibody and we used the 
antibody of Margolis Lab with two dilution of 1:1000 and 1:3000, the first one 
showed much background, the results of the second dilution are shown in Table 
13, but they were no so satisfactory and for this reason we decided to change 
dilution to 1:1500 and determine in the same tissue the presence of CK19 (dilution 
1:50), which is a bile duct marker,  to understand if the non-presence of Bex1 was 
attributable to the conservation of samples. The results in Table 14 show the 
simultaneous presence or absence of CK19 and Bex1, this proves that the 
absence of Bex1 was attributable to bad tissue preservation in 4% formaldehyde. 
For a better optimization we tried five different dilution for Bex1: 1:1500, 1:15000, 
1:50000, 1:100000, 1:150000 and two for CK19: 1:50, 1:100. The results in Table 
15, Fig.22 and Fig.23 show that the best dilution for Bex1 is 1:1500 and for CK19 
is 1:50. [The possibility to dilute the signal out suggesting that it is a specific 
reaction  (not due to the secondary antibody)]. 
Over the correct dilution we tried to find the best protocol for an optimal 
immunohistochemistry. So we tried  to boiled the slides with different antigen 
retrieval buffers: citrate, pH 6, high pH and pH 9 for 10 and 10+10 min; we 
obtained the best performance with pH 9 buffer for 10+10min. We also decided for 
an incubation with primary antibody in a moisture chamber  at 4°C overnight and 
for a counterstain in Mayers haematoxylin for 15min. 
After obtaining the correct dilutions with the correct protocol, we applied these to 
all tissues as shown the Table 16 and Table 17. The samples underlined in Table 
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16 and Table 17 are the best five slides for each disease (only 3 slides for Toxic 
Hepatitis, because we did not have enough samples) of which we took pictures 
with the microscope with four different magnifications (10x, 20x, 40x, 63x), using 
Leica Application Suite – Imaging Software. 
We also tried immunofluorescence on frozen sections to detect CK7 and Bex1, but 
both antibodies for Bex1 (Abcam and Margolis Lab) gave poor results, and for this 
reason we decided to abandon this technique. 
 
The last step was the silencing of Bex1, with Dharmacon® Accell® siRNA on 
HuH7 cell line, to investigate the role of our protein in tumor cells and the pathway 
in which it participates. We decided to use this tecnology because it is independent 
from viral vectors or lipid-based transfection reagents, it can be employed without 
significant effects on cell physiology, it provides delivery into difficult-to-transfect 
cell types and gives a long term gene silencing. 
Huh7 cells were grown in tissue culture medium DMEM + GlutaMAX (450ml), 10% 
FBS (50ml), Gentamicin (2.5ml). Than we transfected part of the cells  with siRNA 
Bex1 SMART Accell, while control cultures not transfected were maintained as 
control. After transfection we used as a growth mediun a mixture of Accell siRNA 
and Accell delivery medium, to allow a long term silencing. 
After incubation at 37°C with 5% CO 2 for 72 hours, cells were silenced, harvested, 
and the protein concentration was determined by theBradford assay at an 
absorbance of 595nm. Table 18 shows the concentration of Bex1 in control and 
silenced samples. 
Thereafter, we performed  Western Blot to evaluate the level of the silencing. We 
loaded in well 4 the control with the concentration of 1,32 mg/ml and in well 5 the 
silenced sample with the concentration of 1,82 mg/ml; we used for the 
immunodetection the Bex1 antibody of MargolisLab, 1:20000 WB. The result in 
Fig.24 shows a clear silencing, because the band in 4 is darker than in 5; but while 
the bands are found at ~62 kDa, Bex1 was expected at ~23 kDa.  
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5 CONCLUSIONS 
 
The results of Real Time PCR show that there is an up regulation of Bex1 during 
liver regeneration in all liver diseases compared to donor liver; instead the 
concentration of Bex2 remains more or less the same, so we decided to focus 
our attention only on Bex1. The most significant increase of Bex1 can be seen for: 
Primary Biliary Sclerosis (PBS), Alcoholic Liver Disease and Paracetamol 
Intoxication. 
These findings open interesting possibilities for exploring Bex1 function in the 
control of liver regeneration, the same role that has been already described in the 
regeneration of axon and skeletal muscle (Koo et al., 2005; Khazaei et al., 2010).  
Indeed immunohistochemistry studies showed that Bex1 is mostly present in the 
bile ducts, and in diseased liver tissues we can found the presence of Bex1 also in 
reactive ductular cells (RDCs) and hepatic progenitor cells (HPC). This confirmed 
the hypothesis that the up regolation of Bex1 has a role during liver regeneration 
after tissue damage.  
 
The knock down of Bex1 in Huh7 cell line  with Dharmacon® Accell® siRNA 
yelded unclears result: a clear reduction of our protein was seen as compared to 
controls, but we expected Bex1 at ~ 23kDa, while the immunoreactive  band was 
found at ~ 62kDa. Further experiments are needed to understand  if the antibody 
recognizes an isoform of Bex in the cell line, or the protein have not been reduced 
sufficiently, or modifications of the protein are involved.  
 
For the future my aim is to examine the function of Bex1 as tumor suppressor in 
hepatocellular carcinoma, in line with its role as tumor suppressor in malignat 
glioma. Bex1 might play an important role in a novel signaling pathway regulating 
apoptosis in hepatic cancer.  Bex1 is already known for being an adapter molecule 
involved in p75NTR/NGFR signaling, with a role in cell cycle progression and 
neuronal differentiation; the generation of Bex1 knock out mice migh help 
understanding its precise role, and in particular its role in liver regeneration.  
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Figure Legends 
 
Fig.1  (Top) The exon–intron gene structure and the chromosomal arrangement of 
the Bex genes on chromosome X in human. (Bottom) The model of gene 
conversion explaining the pattern of sequence evolution in Bex. The brackets 
indicate the portions of Bex involved in gene conversion, and the arrows connect 
the Bex members involved in gene conversion. 
Reference 24 
 
Fig.2  Phylogenetic tree of the human (h), rat (r), and mouse (m) Bex genes. 
Reference 1 
 
Fig.3  Eukaryotic Cell 
http://vvbiology2.wikispaces.com/Eukaryote 
 
Fig.4  Olfactory marker protein 
http://www.antibodies-online.com/antibody/350658/anti-
Olfactory+Marker+Protein+OMP/ 
 
Fig.5  Binding of nerve growth factor 
http://www.nature.com/nrn/journal/v9/n12/fig_tab/nrn2516_F3.html 
 
Fig.6  Cell Cycle 
http://www.bdbiosciences.com/research/apoptosis/analysis/index.jsp 
 
Fig.7  Skeletal Muscle Regeneration 
http://aohs.web2designer.org/muscle-cell-anatomy 
 
Fig.8  Calmodulin (CaM) 
http://zh.wikipedia.org/wiki/File:Calmodulin-Ca.png 
 
Fig.9  Motor Neuron (MN) 
http://home.comcast.net/~pegglestoncbsd/brain%20and%20NS.htm 
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Fig.10 Bex1 expression in axons. MNs from E13-14 mouse embryos were fixed at 
3 days in vitro (DIV) and stained with antibodies specific for Bex1 (green), MAP2 
(red) and the Tau-1 antibody (blue). The scale bar is 40 µm. 
Reference 8 
 
Fig.11 The expression of Bex1 protein, the tissue sections from lumbar-spinal cord 
of MPZ-KO and MAG-KO mice and mice subjected to sciatic-nerve crush-injury or 
demyelination were stained with anti Bex1 (green) and anti-non-phosphorylated 
neurofilament (SMI32; a marker of neurons) (red) antibodies. 4’,6-Diamidino-2-
phenylindole dihydrochloride hydrate (blue) was used for nuclear staining. Scale 
bar is 50 µm. 
Reference 8 
 
Fig.12  HDAC inhibition 
http://www.ifom-ieo-campus.it/research/images/chiocca/fig02.jpg 
 
Fig.13  Overall structure of a portion of a liver 
Reference 20 
 
Fig.14  The two levels of liver regeneration 
Reference 17 
 
Fig.15  Oval cell proliferation 
http://www.medscape.com/viewarticle/463154_3 
 
Fig.16  Protein Bex1 in Donor Liver 
My Picture 
 
Fig.17  The direct method of immunohistochemical staining uses one labelled 
antibody, which binds directly to the antigen being stained for. 
http://en.wikipedia.org/wiki/File:Immunohistochemicalstaining1.PNG 
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Fig.18  The indirect method of immunohistochemical staining uses one antibody 
against the antigen being probed for, and a second, labelled, antibody against the 
first. 
http://en.wikipedia.org/wiki/File:Immunohistochemicalstaining2.PNG 
 
Fig.19  Experimental workflow for Accell siRNA mediated gene silencing and 
detection of mRNA knockdown. 
http://www.dharmacon.com/uploadedFiles/Home/Support_Center/Application_Notes/g
ene-silencing-in-sh-sy5y-and-jurkat-cell-lines-using-accell-sirna.pdf 
 
Fig.20  Coomassie Brilliant Blue 
http://www.piercenet.com/browse.cfm?fldID=02051005 
 
 
 
